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PREFACE 
 Cardiovascular disease is the leading cause of morbidity and mortality in U.S. 
women. Cardiovascular risk screening is recommended for asymptomatic women by 
both national and international cardiovascular experts. This EBP project provides 
compelling evidence that asymptomatic women exhibit a number of modifiable risk 
factors. Such evidence is crucial to demonstrate the imperativeness of primary 
prevention initiatives in the clinical practice setting.  
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ABSTRACT 
Cardiovascular disease (CVD) has long been recognized as a significant health problem 
in the U.S., and is the leading cause of preventable death in women, collectively causing 
about one death per minute (Caboral, 2013). A myriad of modifiable risk factors including 
dyslipidemia, hypertension, smoking, obesity, and type II diabetes are associated with 
80-90% of CVD morbidity and mortality. Despite sobering statistics, valid risk prediction 
screening tools, and national preventive guidelines, adequate screening in clinical 
practice settings is sadly deficient. An evidence-based practice project was designed 
and implemented at a large OB/GYN practice in southern Ohio to address this identified 
gap in clinical practice. Pender’s health promotion model and Stetler’s evidence-based 
practice model provided the theoretical foundation for the project. A critical appraisal of 
current evidence was executed to identify best practice recommendations. The literature 
was salient in articulating that CVD risk assessment in asymptomatic women was 
imperative to guide primary prevention interventions, improves patient outcomes, and 
reduce the economic burden of CVD. Synthesis of the literature supported the use of the 
Framingham risk score (FRS) model as a gold standard recommendation in the clinical 
practice setting. The FRS model was applied to a convenience sample of asymptomatic 
women between the ages of 35-50 who presented for their annual gynecologic exam. 
Statistical analysis using the SPSS 20 statistical software of the gleaned metrics 
demonstrated 91% of the project participants with at least one modifiable CVD risk 
factor. 50.5% (n=55) of the EBP project participants had significant CVD risk factors that 
necessitated a timely follow up appointment. Using Pearson’s r there were 27 
statistically significant relational correlations discerned from the data analysis. The 
findings garnered from the EBP project were commensurate with the findings reported in 
the scientific literature. The data analysis provided compelling evidence to support the 
need for CVD risk screening in asymptomatic women. The literature is salient in 
 xi 
elucidating anywhere from 25-46% of women consider their gynecologist as their PCP, 
therefore, the OB/GYN practice setting is a paramount clinical site for implementation of 
CVD risk screening.  
Keywords: cardiovascular disease (CVD), modifiable risk factors, screening, risk 
prediction models, evidence-based practice, women
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CHAPTER 1 
INTRODUCTION 
Background 
 Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in 
the United States (U.S.). A disease that has traditionally been considered a man’s 
disease is dispelled by statistical data acknowledging that as of 2008, more women in 
the U.S. died from CVD than from all forms of cancer, respiratory disease, and 
Alzheimer’s combined, accounting for one of every three deaths but rapidly approaching 
one of every two deaths (Caboral, 2013). Also, since 1984 the number of CVD deaths 
for women has consistently exceeded those for men (Moran & Walsh, 2013). In 2007, 
CVD caused approximately one death per minute among women in the U.S. (Caboral, 
2013). More than 60% of women who died suddenly of CVD had no previous symptoms 
of CVD (Wood & Gordon, 2012).  
 In asymptomatic women, CVD risk is the additive effect of multiple interacting risk 
factors. Although data indicate an increased cardiovascular mortality in older women, a 
disturbing trend is being observed in young women ages 35-54 (Arslanian-Engoren, 
2011). CVD mortality in this age group has increased 1.3% annually since 1997 
(Arslanian-Engoren, 2011).These sobering statistics reiterate the necessity of primary 
prevention screening and early intervention in women of all ages. 
  CVD is an enormous economic burden accounting for 17% of national health 
expenditures equating to a total of $503 billion in 2010 compared to $228 billion for 
cancer (Owen & Reid, 2013). Between 2010 and 2030, real total direct costs of CVD are 
projected to reach $818 billion (Owen & Reid, 2013).  
 Misperceptions remain pervasive both in the patient population and the medical 
community regarding the significance of CVD in women. A 2009 cross sectional study of 
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2,300 women in the U.S., revealed that only 54% of respondents recognized CVD as 
being the leading cause of death in their gender (Caboral, 2013). This lack of awareness 
is even more poignant in Central Ohio as elucidated by Gulati and Torkos (2011) whose 
survey conducted through Ohio State University revealed that only 22% of Ohio women 
understood the dangers of heart disease. While approximately 75% of the surveyed 
women had CVD risk factors, only 25% identified themselves at risk for CVD. The 
American Heart Association (AHA) released its 2020 Impact Goal of improving the 
cardiovascular health of all American’s by 20% and reducing death from CVD by 20% by 
the year 2020 (Lloyd-Jones, Hong, Labarthe, Mozaffarian, Appel, Van Horn, Greenlund, 
et al., 2010). The AHA has a triad of recommendations to meet their objective which 
includes focusing on prevention at all levels of risk, cognizance that risk factors develop 
early in life, and providing health promotion and disease prevention at both the 
population and individual levels (Heidenreich, 2011). Evidence exists that prevention 
works, specifically that >50% of reduction in CVD mortality is due to changes in risk 
factors and 40% to improved treatments (Perk, DeBaker, Gohlke, Graham, Reiner, 
Verschuren, Albus, et al. 2012). 
 Multiple barriers to assessment of CVD risk factors in women have been 
identified in the literature. Lack of access to care and lack of knowledge and skill in 
guideline implementation among internists, family practitioners, and gynecologists are 
among the barriers identified. For instance, in a study evaluating the impediments in 
CVD prevention, one half of obstetricians-gynecologists and one third of internists 
surveyed were unaware that tobacco use is the leading cause of myocardial infarction 
(MI) in younger women (Mosca, Benjamin, Berra, Bezanson, Dolor, Lloyd-Jones, 
Newby, et al., 2011).  
 A myriad of risk factors interact synergistically to increase the level of CVD risk. 
The majority of these risk factors are modifiable such as dyslipidemia, body mass index 
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(BMI), blood pressure, smoking, nutrition, and inactivity. Non-modifiable risk factors 
include age, sex, ethnicity, and family history. CVD risk factor modification targeting 
lifestyle behaviors (smoking, sedentary lifestyle, poor diet) and comorbid conditions 
(hypertension, dyslipidemia, diabetes, and obesity) have the propensity to profoundly 
impact CVD burden.   
 According to the AHA (2012), 53.8 million women have total blood cholesterol 
(TC) levels of ≥ 200 mg/dL (Moran & Walsh, 2013). Dyslipidemia as a cardiovascular 
risk factor affects women differently than men. Elevated triglycerides (TG) (>200 mg/dL) 
and low levels of high-density lipoprotein (HDL) cholesterol (<40 mg/dL) are more potent 
independent risk factors for women than for men (Edwards, 2012). A meta-analysis of 17 
population based prospective trials demonstrated an 88 mg/dL increase in plasma 
triglyceride levels was associated with an increase in relative risk of CVD of 75% in 
women compared to 30% in men (Edwards, 2012).  
 An ominous trend of rising obesity rates now affects nearly two of every three 
American women ≥ 20 years of age (Mosca et al., 2011). Overweight or obese as 
defined as a BMI of ≥ 25.0 kg/m² affects 71.3 million women above the age of 20 (Moran 
& Walsh, 2013). In the United States, 66% of Americans are now considered overweight 
or obese (Gleeson & Crabbe, 2009). Obesity, especially central adiposity, is recognized 
as one of the most important modifiable cardiovascular risk factors. Based on population 
studies risk estimates indicate at least two thirds of the prevalence of hypertension can 
be directly attributed to obesity (Chrostowska, Szyndler, Hoffmann, & Narkiewicz, 2013). 
In men, the attributable risk of hypertension induced by abdominal obesity ranges from 
21% to 27% whereas in women the range is 37% to 57% (Chrostowska, Szyndler, 
Hoffmann, & Narkiewicz, 2013). Among individuals in the Framingham Heart Study, 
obesity increased the relative risk of CVD by 64% in women (Sharma & Gulati, 2013). In 
addition to the direct health consequences of obesity, medical expenditures attributed to 
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adult obesity totaled $147 billion in 2008 and are predicted to be greater than $300 
billion by 2018 (Shaw, Caughey, & Edelman, 2012). Obesity and adipose tissue itself 
have direct and deleterious effects on cardiovascular function and structure. Not only is 
obesity an independent risk factor for CVD and hypertension but it also contributes to 
dyslipidemia, and Type II diabetes.  
 Hypertension is an important causative factor in the lifetime risk for developing 
heart failure with a reported risk of one in six for women without prior history (Gleeson & 
Crabbe, 2009). The evidence linking untreated hypertension to increased cardiovascular 
morbidity and mortality is undisputed. In terms of attributable death, the current leading 
cause of CVD risk and mortality is elevated blood pressure. A large systematic review of 
147 trial reports on the management of hypertension has shown that a mere reduction of 
10 mm Hg in systolic blood pressure and 5 mm Hg in diastolic blood pressure was 
associated with a 20% reduction in CVD and 32% reduction in stroke in one year (Al-
Ansary, Tricco, Adi, Bawazeer, Perrier, Al-Ghonaim, AlYousefi, et al., 2013). Elevated 
blood pressure contributes to 7.6 million worldwide premature deaths annually (Turnbull, 
Kengne, & MacMahan, 2010).  
 Smoking has an associative affect in a plethora of diseases and is responsible 
for 50% of all avoidable deaths in smokers, half of these due to CVD (Perk, DeBacker, 
Gohlke, Graham, Reiner, Verschuren, Albus, et al., 2012). Smoking is known to cause 
inflammation and thrombotic activity with epidemiologic evidence supporting a dose 
relationship between the number of cigarettes smoked and resultant CVD risk. Reports 
by the U.S. surgeon general conclude that smoking is the single greatest cause of 
avoidable morbidity and mortality in the U.S. (Filion & Guepker, 2013). In women under 
the age of 50, cigarette smoking significantly increases the risk for a first MI compared to 
men (Gleeson & Crabbe, 2009). 23% of women who have an MI in their 40’s will die 
within one year of the cardiovascular event (Johnson & Seibert, 2011). The 
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INTERHEART study found that the risk for MI increased by 5.6% for every additional 
cigarette smoked per day (Owen & Reid, 2013). Smoking also negatively interacts with 
several other CVD risk factors such as hypertension, dyslipidemia, and diabetes.  
 A Cochrane systematic review found that smoking cessation was associated with 
a significant (36%; odds ratio (OR) =0.64, confidence interval (CI) 95%) reduction in risk 
of all-cause mortality in patients with CVD (Katskiki, Papadopoulou, Fachantidou, & 
Mikhailidis, 2013). Smoking cessation is an effective CVD prevention strategy; within 
three years of quitting, risk of MI in the INTERHEART Study had halved (Owen & Reid, 
2013). Despite these pervasive statistics, 18.1% of all women in the U.S. continue to 
smoke (Wood & Gordon, 2012). 
 Type II diabetes is another significant risk factor for the development of CVD. 
According to the Centers for Disease Control and Prevention (CDC), 11.5 million women 
ages 20 and older have diabetes. CVD death rates are increased three to fourfold in 
women with diabetes compared to men (Arslanian-Engoren, 2011). Diabetes 
accelerates the atherosclerotic process which is commensurate with increasing a 
person’s age by approximately 15 years (Worrall-Carter, Ski, Scruth, Campbell & Page, 
2011). Type II diabetes is a completely preventable disease which can be averted 
through weight management, nutrition, and physical activity.  
 Physical inactivity is yet another modifiable CVD risk factor. Only about 31% of 
American women age 18 and older engage in 30 minutes of moderate physical activity 
five times per week as recommended by the AHA (Arslanian-Engoren, 2011). There is 
limited randomized data on the independent effects of exercise on the primary 
prevention of CVD events, however multiple prospective and retrospective observational 
studies have shown that regular exercise is associated with lower rates of CVD (Hsu, 
Van-Khue, Ashen, Martin, Gluckman, Kohli, Sisson, et al., 2013). The inverse 
relationship between physical activity and risk for developing CVD is present in both men 
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and women but is more pronounced in women. The median CVD risk reduction in 
women was 40% when most active (30 minutes per day) women were compared to least 
active women, whereas that in men was 30% (Shiroma & I-Min, 2010).  
 In summary, each identified cardiovascular risk is significant in and of itself but 
when multiple risk factors are present, the risk exponentially increases. This further 
validates the importance of obtaining a complete CVD risk assessment on asymptomatic 
women in the clinical setting.  
Statement of the problem 
 The problem that the evidence-based practice project addressed was CVD risk 
identification and stratification in asymptomatic women. The rationale for using a risk 
prediction model is that in the majority of adults, CVD is the product of greater than one 
risk factor; it is the synergistic effect of multiple risk factors over time. The majority of 
CVD, (80-90%) is modifiable, but unless women are being screened for CVD risk, 
interventions on lifestyle modification cannot be initiated. Mosca, Benjamin, Berra, 
Bezanson, Dolor, Lloyd-Jones, Newby, et al., (2011) found that in the three years after 
distribution of guideline recommendations for use of the Framingham-based risk scoring, 
less than 50% of primary care physicians were implementing them. The aim of CVD risk 
assessment is to be more effective in identifying those at risk and to facilitate evidence-
based prevention and treatment based modalities.    
 Over the past 20 years, studies have shown that women are less likely than men 
to be evaluated for CVD risk factors. Despite reliable CVD risk screening tools, there is a 
prevalent disconnect between what is recommended for risk assessment and the reality 
of what is being done in clinical practice. It is the responsibility of the practicing clinician, 
in providing comprehensive care, to perform CVD risk assessment on asymptomatic 
patients.  
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Data from the literature supporting the need for the project   
An amalgamation of numerous large-scale clinical trials and systematic reviews 
has informed our understanding of cardiovascular risk factors and disease. The 
“Effectiveness-Based Guidelines for the Prevention of Coronary Artery Disease in 
Women-2011 Update” recommends risk-stratifying women based on their risk scores 
into three categories: 1) high risk; 2) at risk; and 3) optimal risk (Sharma & Gulati, 2013). 
As has been previously articulated, a handful of modifiable risk factors account for 80-
90% of CVD. Optimization of these easily measured and potentially modifiable risk 
factors could result in a 90% reduction in risk for an initial MI (Berger, Jordan, Lloyd-
Jones & Blumenthal, 2009). 
 CVD death rates had been declining between 2000 and 2008 largely due to 
advancements in secondary prevention (47%) and risk factor reduction (50%) (Perk et 
al., 2012). These statistics support CVD risk factor modification to be profound in 
reducing future CVD events in women. However, increasing obesity rates and greater 
prevalence of diabetes has reversed the downward trend and has demonstrated 
increasing annual CVD death rates of 8% and 10% respectively (Ehrenthal et al., 2011).  
 Given the social burden of premature death, disability from CVD, and escalating 
costs of CVD, there must be a paradigm shift in the approach to cardiac care from 
treatment of single risk factors in isolation and opportunistic screening to systematic 
screening and to the management of total cardiovascular risk. Risk assessment through 
a validated predictive tool and management of CVD risk factors has been recommended 
both nationally and internationally by experts in the field as a prudent primary prevention 
strategy.  
 A recent study was conducted by the Cardiovascular Research Foundation 
(CRF) in ten OB/GYN offices which assessed 2,234 asymptomatic middle aged women 
for CVD risk factors. The results were astonishing; 87% of the women had CVD risk 
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factors while 42% had cardiovascular symptoms (Jancin, 2012). Of the women screened 
14% had hypertension, 21% were dyslipidemic, and 7.5% had diabetes. Of the 
participants assessed, 18% of the participants identified their gynecologist as their 
primary care provider while 6% identified no primary care provider at all (Jancin, 2012). 
In a review authored by Scholle & Kelleher (2003) 38% of the respondents identified 
their gynecologist as their primary care provider. A screening pilot program conducted by 
SCAI-Women in Intervention (2012) garnered cardiovascular risk factor data on over 
3000 women visiting their OB/GYN office. Over 70 percent of the women screened at 16 
study sites had CVD risk factors while 40 percent of them were actually experiencing 
cardiovascular symptoms. This study also touted the significant percentage of women 
who cite their OB/GYN as their primary care provider.  
 Improving cardiovascular health of all Americans is a national priority with a goal 
of reducing CVD morbidity and mortality and decreasing health care financial 
expenditures. The OB/GYN as an identified practice setting must embrace the national 
recommended guidelines for CVD risk assessment in asymptomatic women as an 
initiative to reduce cardiovascular burden and improve the health of women in the U.S.  
 A great number of CVD prevention guidelines and tools are reported in the 
literature and proclaimed by various national and international organizations as being 
superior to another. However, the ultimate objective of all CVD screening guidelines is 
identical: to facilitate the prevention of CVD and all its clinical manifestations (De Backer, 
Catapano, Chapman, Graham, Reiner, Perk, & Wiklund, 2013). Guidelines should be 
simplistic, straightforward, and credible, applicable to the patient population, and be an 
aide for informed decision making between the provider and the patient. 
 The FRS, developed through the Framingham Heart Study (1971-1974), is one 
of the earliest and best known epidemiological studies in the field of cardiovascular 
disease. The FRS is the most commonly recommended assessment tool for evaluating 
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the risk stratification of CVD in the U.S. (Setayeshgar, Whiting, & Vatanparast, 2013). 
The critically appraised literature repeatedly recommended the FRS as the gold 
standard for evaluating risk and differentiating high-risk from low-risk women. Key 
cardiovascular risk factors from the identified Evidence based practice (EBP) project 
study population was inputted into the web-based FRS prediction equation for numerical 
probability that the individual will develop CVD over a specific time period, generally a 
ten year time frame. Additionally, the FRS provided a vascular heart age based on the 
gleaned metrics for further informing. Further discussion of the FRS will be detailed in 
the method section of chapter three.   
Data from the clinical setting supporting the need for the project  
It is essential in clinical practice to be able to assess cardiovascular risk 
precipitously and with sufficient accuracy to allow logical management decisions. 
Lifestages Center’s for Women is a large multi-site OB/GYN practice located in Southern 
Ohio and served as the EBP project implementation venue. The mission statement of 
Lifestages includes a commitment to providing health and wellness services to women of 
all ages. Lifestages recognizes its responsibility to the community, to not only advocate 
for, but to develop and implement quality, comprehensive, and cost effective health care 
programs which educate, inform and support women in making their health care choices 
and living healthful lives. The provider staff of Lifestages includes OB/GYN physicians, 
certified nurse midwives (CNM), and a board certified family nurse practitioner (FNP). 
 The Samaritan north practice site served as the implementation site for the EBP 
project and sees on average a hundred women per day. Traditionally the OB/GYN 
practice setting has focused on reproductive and gynecologic health not on 
cardiovascular health; however as previously elucidated, 25%-46% of women consider 
their OB/GYN as their primary care provider (PCP). Sadly, as presented by Mosca et al, 
(2011) only one in five physicians knew that more women than men die each year from 
SCREENING CARDIOVASCULAR RISK  10 
 
CVD and interestingly, OB/GYN physicians were reported to have substantially less 
awareness of national risk assessment guidelines compared to other physicians. Based 
on the reported literature, these statistics are detrimental to a woman’s health and the 
provider group at Lifestages has collectively agreed to become proactive in reversing 
this ominous trend.  
 Effective nurse leaders are essential to play key roles in shaping the health care 
delivery system and addressing primary prevention measures of risk assessment and 
intervention modalities for modifiable CVD risk factors. As a family nurse practitioner 
(FNP), this Doctor of Nursing Practice (DNP) project manager will be instrumental in 
assessment, education, and treatment of women at risk for CVD.  
Purpose of the EBP project 
 All women are at risk for CVD; therefore, preventive screening based on 
demographic characteristics, comorbid conditions, lifestyle behavior, and risk factor 
assessment should be routinely performed in the clinical setting in accordance with 
national guidelines. The first step in disease prevention is recognizing risks which can 
only be accomplished through performing screening assessments. Screening involves 
the routine evaluation of asymptomatic people for detection of risk or disease. Available 
clinical data suggest that CVD is largely preventable and incremental benefits exist from 
identification and improved control of modifiable CVD risk factors. The purpose of this 
EBP project was to screen asymptomatic women between the ages of 35-50 presenting 
for their annual gynecologic exam for cardiovascular disease risk and stratification. This 
approach affords a valuable tool for identifying a cohort of women who can benefit from 
preventive treatments to modify or reverse CVD progression. Ultimately, efforts must 
focus on expanding the number of women whose level of risk is accurately identified and 
who are receiving evidence-based interventions for CVD risk reduction.   
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The clinical question 
 The burning clinical question is: can asymptomatic women be accurately 
identified for CVD risk factors and have their level of cardiovascular risk accurately 
stratified? The advantage of implementing a standardized reliable risk assessment tool 
is that it should be intuitively easy to initiate, takes into account the multifactorial nature 
of CVD, assesses the appropriate variables, allows for a consistent measurement of risk 
over time, and establishes a common language that can easily be understood among 
practitioners. 
PICOT 
 In women between the ages of 35-50 presenting for their annual gynecologic 
exam, who are asymptomatic for cardiovascular disease, how does implementation of 
the Framingham risk assessment model, compared to usual care (no screening), identify 
the level of CVD risk over a three month period of time? 
Significance of the project 
 In reality, 38.2 million U.S. women are living with some form of CVD while a 
significantly higher percentage of women are at increased risk for developing CVD 
(Carey & Gray, 2012). Beneficial reductions in major risk factors such as smoking, blood 
pressure, and high cholesterol, account for more than half of the decreases in CVD 
deaths (Perk et al., 2012). It is therefore imperative to implement CVD screening risk 
assessment to identify and implement interventions to improve clinical outcomes and 
reduce healthcare costs. Current guidelines emphasize assessing a woman’s CVD risk 
factors throughout her lifetime. After the age of 50, women with even one risk factor will 
have a substantially higher lifetime risk of developing CVD (Gleeson & Crabbe, 2009).  
 The ultimate goal of the EBP project is identifying asymptomatic women for their 
cardiovascular disease risk within the OB/GYN practice setting. The OB/GYN practice 
site has not traditionally assessed women for disease not related to the reproductive 
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system. The reasoning behind this has been multi-factorial and includes lack of 
awareness, lack of understanding and comfort level of garnering metrics on CVD, feeling 
that it is the responsibility of the PCP to screen, not being comfortable treating risk 
factors for CVD, and not having a referral mechanism in place. In the implementation 
site for the EBP project, some of these barriers were articulated; however assurance 
was rendered to the clinical provider staff that the FNP would be responsible for patient 
follow up and referral.  
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CHAPTER 2 
THEORETICAL FRAMEWORK AND REVIEW OF LITERATURE 
 In this chapter, the DNP project manager will discuss the two theoretical 
frameworks that were used to guide the EBP project. The strengths and limitations of the 
framework and its applicability to the project will be discussed. A review and appraisal of 
the literature that supports the underpinnings of the project will be addressed in detail.  
Theoretical framework 
 The theoretical frameworks chosen for this EBP project were Norla Pender’s 
Health Promotion Model (HPM) and the Stetler model of EBP. These models were 
chosen for their applicability to the EBP project. Each of the frameworks will be 
discussed in detail in the following section. 
Description of the theoretical framework 
The HPM was developed by Norla Pender as a holistic predictive model of health 
promoting behavior for application in the clinical practice setting. The model attempts to 
explain and predict human behavior in regard to individual health choices and behavior. 
The HPM has its theoretical roots in the expectancy value theory and the social cognitive 
theory. The expectancy theory purports that individuals engage in actions to achieve 
goals that are perceived to be possible and that have valued outcomes (Strof & Velsor-
Friederich, 2006). The social cognitive theory reveals the interconnectedness of 
thoughts, behavior, and environment in their effect on behavior (Strof & Velsor-
Friederich, 2006). Pender articulates that health promotion, defined as behavior 
motivated by the desire to increase well-being and actualize human health potential, and 
disease prevention, defined as behavior motivated by the desire to avoid illness, should 
be the primary impetus in health care (Pender, Murdaugh, & Parsons, 2011).  
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The HPM has been validated in numerous clinical studies. With regard to the 
benefit of action of the model, the test-retest reliability score is 0.86 and Cronbach’s 
alpha is 0.75-0.88; in the barriers to action component of the model the test-retest 
reliability is 0.75 and Cronbach’s alpha is 0.75-0.84 respectively (Pender, Murdaugh, & 
Parsons, 2011).  
 One of the most challenging roles for the practicing clinician is to identify the 
motivating factor that will provide the impetus for eliciting health behavior change in the 
patient. The goal of primary prevention is to focus on being proactive with one’s health 
versus being reactive when disease occurs. There are eight maxims of the HPM that 
purport to characterize health behavior. The first maxim is the perceived benefit of the 
action that must be realized by the patient: the individual must foresee the positive 
consequences of undertaking a health behavior change. Secondly, the patient must be 
able to identify the perceived barriers to action, the perception of blocks and personal 
costs of undertaking a health behavior change. The third maxim is perceived self-
efficacy and the judgment of personal capability to organize and execute a particular 
health behavior and complete it successfully. The fourth maxim is the activity-related 
affect involving the emotional component of health during and following a specific health 
behavior. The fifth maxim revolves around the interpersonal influences of family, peers, 
and healthcare providers. This may be the most tenuous construct to achieve as the 
interactions and compelling forces of peers and family outside of the clinical practice are 
typically more persuasive than the advice and recommendations of the healthcare 
practitioner. The sixth maxim involves situational influences or the perception of the 
compatibility of life context or environment with engaging in a specific health behavior. 
The seventh maxim is the commitment to a plan of action with the intention to carry out a 
particular health behavior including the identification of specific strategies to do so 
successfully. Lastly, the patient must evaluate the immediate competing demands and 
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preferences that deter changing health behaviors. It is commonplace in clinical practice 
to hear a barrage of reasons for not completing or continuing a health behavior change. 
As a clinician, these excuses must be discussed and a plan formulated to repudiate 
these barriers so that the patient can actively pursue behavioral change.  
 Research has shown that an individual will take health-related action when there 
is “a perceived threat to personal health and when the conviction that the benefits of 
taking the action to protect health outweigh the barriers that will be encountered” 
(Pender, Murdaugh, & Parsons, 2011, p. 38). One of the roles of the healthcare provider 
is to discern what the perceived health threat would be to each individual patient and 
capitalize on that belief to effect change in health behavior.  
Application of the theoretical framework to the EBP project 
  Health promotion and disease prevention should be the primary emphasis within 
the health care environment. It has been succinctly elucidated that the majority of 
cardiovascular risk factors are modifiable. After critical assessment of numerous 
theoretical foundations, it was determined that the Pender model is particularly 
applicable to this EBP project. The HPM provides an excellent foundation for guiding the 
identified cohort to become actively involved in health promotion and prevention 
outcomes. Young and Capezuti (2010) postulated that the health promotion model 
allows for examining factors associated with improved health promotion and allows 
focusing on personal and environmental factors that influence health. It is imperative for 
patients to change their modifiable risk factors in order to prevent or reduce the burden 
of CVD. The eight maxims of the HPM clearly delineate behavior and cognitive 
constructs that determine health promoting behaviors. The health promotion model has 
been validated in research to be beneficial in promoting positive health behavior change 
in people. 
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Strengths and limitations of the theoretical framework  
The primary concern for health care providers is to promote health and prevent 
disease for each individual patient. The principal strength of the HPM is the identification 
of factors that influence health behavior. Evaluation of the eight maxims provides a 
logical progression to improve heath and health behaviors. The definitions of the 
concepts are clear and unencumbered, making them easily understood by health 
professionals. Strof and Velsor-Friederich’s (2006) analysis of the HPM indicates that 
self-efficacy and behavior specific cognitions are supported as a predictive variable in a 
myriad of studies. Identification of benefits and barriers to positive health behavior plays 
a role in predicting individual health behavior.  
 The HPM would ideally empower patients with unhealthy behaviors to make 
necessary changes to promote and improve their health. The HPM can be a beneficial 
tool for increasing patient awareness and perception of CVD risk factors and facilitating 
positive behavioral health change. Bennett, Perry, and Lawrence (2009) believed that 
health behaviors must be in the control of the patient and possess meaning for the 
patient in order to be effective. Using the HPM as a framework while interacting 
collaboratively with the patient, the clinician can identify the barriers that impede patients 
from achieving optimal health.  
 One of the limitations to the HPM is that the relationship between the constructs 
is not clearly identified. Although interrelated, there is not a clear linear relationship 
between the various constructs. Some constructs are more powerful than others in 
affecting health care behavior. Peterson & Bredow (2009) articulated: “Although the 
model identifies foci for nursing interventions, it does not explicitly describe how nurses 
can effect changes in client perceptions” (p. 296). Practitioners in a busy clinical setting 
may find evaluation of eight constructs to be cumbersome and untenable as well as time 
prohibitive.  
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 There are specific assumptions associated with the HPM including the 
assumption that patients are able to self-reflect, actively seek to regulate behavior, and 
initiate behaviors that modify their environment (Pender, 1996). This may not be the 
case with each individual patient.  
 Time constraints of a routine clinical visit would preclude identification of all 
tenets of the theoretical model and their level of significance for each individual patient. 
Assisting patients to address the perceived barriers such a lack of discipline, 
interference by family and peers, and application of change in daily behavior would be a 
daunting time intensive task. The interaction of patient and provider regarding health 
changing behavior and risk modification must be persistent and undeviating to effectively 
elicit health behavior change. Although Pender removed threat of disease from her 
original model, Peterson and Bredow (2009) pointed out that this may not always be 
distinguished in practice; threat of disease may therefore continue to be a motivational 
factor in promoting changes in health behavior. An additional barrier to implementation 
of the HPM may be that the clinician doubts the patients’ willingness to change negative 
behaviors and thus finds health promotion and disease prevention discussions to be a 
waste of valuable time.  
 In summary, the HPM does provide a sound theoretical framework for promoting 
change in health behavior. The HPM identifies individual behavior and factors that 
restrict positive health promoting behavior. The premise of the model is to concentrate 
on the barriers that impede individuals from achieving optimal health and preventing 
disease. This model is persuasive for promoting CVD risk reduction in asymptomatic 
women by identifying barriers, strengthening potential and capability, and putting the 
responsibility for one’s health in their own hands making the patient a positive change 
agent.   
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Description of the EBP model 
 The principles of EBP have become the cornerstone strategy for health care 
providers to translate research into clinical practice (Facchiano & Hoffman-Snyder, 
2012). Evidence-based practice is a problem solving approach to clinical care that 
incorporates the conscientious use of current best evidence from well-designed studies, 
a clinician’s expertise, and patient values and preferences (Fineout-Overholt, Melnyk, & 
Schultz, 2005). The ever-changing health care environment compels practitioners to 
synthesize the highest level of evidence into the decision making process. Although 
there are a number of definitions used interchangeably for evidence-based medicine and 
evidence-based practice, one of the most widely accepted definitions is by Sackett, 
Rosenberg, Gray, Haynes, and Richardson (1996) who defined evidence-based 
medicine “as the conscientious, judicious, and explicit use of current best evidence in 
making decisions about the care of the individual patients” (p.71). The intent of EBP is 
not to conduct new research but rather to synthesize clinical evidence from high levels of 
previously published research and apply it to the clinical setting and to the individual 
patient. Facchiano and Hoffman-Snyder (2012) concluded that “EBP is a strategy to 
keep knowledge up to date, enhance clinical judgment, and lead to cost-effective 
treatment modalities” (p.581). The Institute of Medicine (IOM, 2001) confirmed that it is 
germane to base clinical decision making on scientific acumen that is evidence-based. 
When EBP processes are integrated into our clinical practice settings they augment the 
existing provider-client relationship and shared decision making process (Facchiano & 
Hoffman- Snyder, 2012). The IOM (2001) has set forth a recommendation that 90% of all 
clinical decisions be evidence-based by the year 2020. The EBP model chosen for this 
project is the Stetler model of evidence based practice.  
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Application of the model to the EBP project 
  Cheryl Stetler’s model of research utilization was one of the original models 
developed for EBP. She originally developed the model in 1994 and then revised it in 
2001. The purpose of the model is to formulate a series of critical thinking and decision 
making steps that are designed to facilitate effective use of research findings (White & 
Dudley-Brown, 2012). The Stetler model de-emphasizes practice based on tradition and 
instead focuses on the use of research findings along with other credible sources of 
data. The model focuses on both internal data (such as quality improvement, 
operational, evaluation, and practitioner experience) and external data (such as primary 
research and consensus of national experts) making the model comprehensive in nature 
(Ciliska, et al., 2011).  
 The Stetler model is a series of five progressive critical thinking and decision 
making steps designed to facilitate use of research findings in the clinical setting. 
Preparation, validation, comparative evaluation/decision making, translation/application, 
and evaluation represent the five building blocks of the model (Ciliska, et al., 2011).  
 The preparation phase initiates the EBP process by defining the clinical issue, 
identifying the purpose, and affirming the priority of the identified clinical question. During 
the initial phase consideration is given to both internal and external factors which may 
create barriers to implementation. Potential barriers may include organizational 
expectations/norms, peer expectations, resource availability, and timelines. The PICOT 
question is formulated to clarify and organize the patient population, intervention of 
interest, comparison of interest, outcome of interest, and timeframe of the project (Romp 
& Kiehl, 2009). It is during the preparation phase that the researcher identifies 
measurable outcome goals and expectations for the project. 
 The clinical issue identified by this DNP project manager relates to the lack of or 
inconsistency of CVD risk screening in the female clients seen at Lifestages Center’s for 
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Women. To reiterate the significance of this clinical issue, CVD being the leading cause 
of death in women, is predominantly precipitated by modifiable risk factors. The clinical 
conundrum is that unless CVD risk screening is implemented in the clinical setting and 
risk identified, there cannot be evidence based interventions initiated. It is therefore 
prudent to implement a primary prevention modality to identify cardiovascular risk in 
asymptomatic women. This DNP project manager, being an FNP, practices primary care 
within an OB/GYN office setting. Many women identify their gynecologist as their primary 
care provider, especially women of childbearing age. The usual CVD risk screening may 
be opportunistic at best in this clinical setting. Not screening asymptomatic women for 
cardiovascular risk in the clinical setting is negligently ignoring a disease that can easily 
be modified to change the trajectory of cardiovascular disease progression. This DNP 
project manager has been afforded a pristine opportunity to amass data on CVD risk 
factors and stratification of risk in asymptomatic women presenting for their annual 
preventive exam. This EBP project is a primary prevention intervention initiative.   
 Phase two of the Stetler model is the validation phase in which relevant literature 
is critically appraised and synthesized for its applicability to the PICOT question. The 
methodological review discerns adequate evidence to support the PICOT question. The 
evidence is analyzed for its statistical and clinical significance as it relates to the clinical 
question. The chosen evidence is rated for its level and quality and catalogued in an 
evidence table for easily accessible visualization. It is during this phase that reflection of 
the studied variables and their relationships are assessed in terms of their applicability to 
the clinical practice issue. Although a number of tools would provide CVD risk 
stratification, the tool must be easily applied to the identified cohort and the practice 
setting. The review of literature will be succinctly detailed in a following section. 
  Comparative evaluation/decision making is the third phase of the Stetler model. 
Rigorous comparison of the cumulated evidence for similarities and differences is 
SCREENING CARDIOVASCULAR RISK  21 
 
completed and the most applicable evidence for the project is garnered. Many sources 
of evidence may be pertinent to the EBP but a myriad of parameters must be taken into 
consideration such as feasibility, cost, time constraints, current practice fit, and 
organizational buy-in before a final decision is made. Admittedly there are a 
multitudinous number of risk prediction models articulated in the literature however, this 
DNP project manager chose the Framingham risk prediction model for its reliability, 
validity, national clinical guideline recommendations, and ease of use in the clinical 
practice setting.  
 Phase four of the Stetler model is the translation/application phase. Using the 
summary statements from phase three, the DNP project manager articulated 
implementation methodology of the synthesized findings specific to the EBP project. This 
phase specifically delineates the type of research, method of use, level of use, any 
variation of use, and the plan for dissemination and change strategies (Stetler, 2001).  
 A convenience sample of women between the ages of 35-50 who presented to 
Lifestages Samaritan North office for their annual gynecology exam, and who were 
asymptomatic for CVD, were offered CVD risk assessment. Women were assessed by 
the nursing staff for inclusion/exclusion criteria, the nursing staff obtained informed 
consent, inputted demographic and measurement values onto the questionnaire, and the 
medical practitioner seeing the patient ordered a fasting lipid and metabolic panel if not 
previously done within the past 12 months. The questionnaire along with the laboratory 
metrics were forwarded to the DNP project manager for input into the web-based risk 
prediction tool database.  
 Implementation of a practice change can be challenging therefore, a myriad of 
methods of dissemination of information to key stakeholders must be considered. 
Communication was done via provider meetings, staff meetings, individual meetings, e-
mail reminders, personal interaction with providers and staff, use of power point 
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presentations, as well as active involvement by the marketing director and practice 
manager. Data collection and coalescing of data took place over a 12 week time period.  
 Tacit valuing, enthusiasm, and awareness of the EBP project are consequential 
for its success in the clinical practice setting. Anticipation of potential barriers and 
methods to circumvent these barriers must be in place prior to the implementation 
phase. This DNP project manager was available at all times, either physically present in 
the practice setting or via telecommunication, should obstacles be encountered. 
 Phase five of the Stetler model is the outcome/evaluation phase. Evaluation of 
the EBP project was based on expected outcomes relative to the PICOT question. 
Differentiation of formal and informal evaluation as it relates to applying the findings to 
clinical practice was rendered. Statistical analysis using the SPSS 20 statistical software 
was completed on the garnered data for its significance and credibility to the clinical 
question. Assimilation of the findings was disseminated to the provider and nursing staff 
through group staff meetings and power point presentations. The final phase of the 
Stetler model is continuous and ongoing as the practice change is made a permanent 
change in clinical practice.     
 The Stetler model is a practitioner-oriented model with a focus on critical thinking 
and the application of research findings applied by an individual practitioner. The model 
maintains the core assumptions that research based recommendations are applied at 
the skilled practitioner level to individual patients or other identified groups (Melnyk & 
Fineout-Overholt, 2011).  Albeit the Stetler model is an individual practitioner oriented 
model rather than an organizational focused model, it is desirable to have a supportive 
organizational culture. The organizational culture must propagate leadership support for 
evidence-based practice foci, have the capacity to engage in EBP, have an effective 
implementation framework, and have an infrastructure to maintain an EBP milieu. The 
choice of this model was in part due to a collective acknowledgement within the provider 
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group identifying the exigency to screen women for cardiovascular disease risk. The 
leadership culture supports the EBP project and deems it crucial in meeting primary 
prevention goals and in providing comprehensive healthcare screening to women. 
Implementation of the EBP was an individual practitioner endeavor with expected 
outcome and data analysis to support the commitment to continue cardiovascular risk 
screening as an organization wide endeavor.  
Strengths and limitations of the EBP model in the context of the EBP project  
The Stetler model of EBP provides a conceptual framework to elicit a clinical 
practice change. The models assumptions and action steps are grounded in research 
and are interactive in nature. The model emphasizes critical thinking and is intended for 
the practicing clinician. The model affirms the expertise and experience of the clinician to 
apply evidence-based guidelines in the clinical practice setting. The logical progression 
of the various phases of the model provided substantiating evidence to support a 
needed change in current clinical practice. Critical appraisal of the evidence helped 
ascertain the best fit for answering the clinical question and aided in identifying the 
evidence that was most apropos for use in the OB/GYN clinical setting. 
 A potential limitation to the model is the paucity of change theory discussion 
within the implementation phase of the model. Change causes angst both individually 
and collectively within the work environment. Staff may perceive the screening 
implementation to be more work for them, staff may feel that the traditional way of doing 
things is fine, and concern arises as to what will be done with the data garnered from 
implementing a risk assessment screening. Providers have voiced concern regarding 
their level of comfort in primary prevention screening and their responsibility in 
relationship to intervention and referrals based on risk prediction scores. These 
concerns were encompassed as part of the education prior to implementation and were 
ongoing throughout the EBP project.  
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  The decisions rendered during a clinical practice change and used within the 
context of practice must be replicable, observable, credible, verifiable, and supportable 
(Melnyk & Fineout-Overholt, 2011). EBP is a strategy to keep knowledge up to date, 
enhance clinical judgment, and lead to cost-effective treatment modalities (Facchiano & 
Hoffman-Snyder, 2012). Adopting EBP in the clinical setting enables the clinician to 
present EBP recommendations to patients and involve them in the clinical decision 
making process. 
Literature search 
 Using key words from the PICOT question, a cogent number of health care data 
bases were searched for current relevant evidence related to cardiovascular risk 
assessment in asymptomatic adults. In alignment with the evidence-based process, 
rigorous research must be appraised and be included in the clinical practice setting to 
improve the quality of healthcare and patient outcomes (Melnyk & Fineout-Overholt, 
2011). This DNP project manager searched a salient number of word combinations and 
phrases to compile a body of evidence that best related to the EBP project and the 
PICOT question. This rigorous search for evidence was labor intensive and difficult to 
amalgamate into tangible units of useable information. There was a dearth of evidence 
on CVD risk factors and cardiovascular prediction models to appraise and classify.  
Sources examined for relevant evidence  
The search engines used for ascertaining highly relevant current evidence 
included: CINAHL, Joanna Briggs Institute (JBI), Cochrane databases, PubMed, Google 
Scholar, National Guideline Clearinghouse, and MEDLINE via EBSCO. A combination of 
search terms used in each search engine included: cardiovascular disease, women, 
cardiovascular risk assessment, screen, tools, interventions, cardiovascular risk factors, 
and Framingham heart study. 
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 Inclusion criteria consisted of peer reviewed scholarly journals, evidence-based 
or research articles, English language, and date range of 2008-2013. Exclusion criteria 
were articles written in a foreign language, research older than 2008, evidence that was 
not pertinent to the evidence-based project, and sources that were not high levels of 
evidence.  
 In the CINAHL database, an initial search using the identified terms yielded a 
total of 31 articles that matched the search criteria. Of these identified articles, five were 
pertinent to the evidence-based project. Of these research articles, two were included in 
the appraisal of evidence due to their applicability to cardiovascular risk factor 
identification and the pertinence of the Framingham risk score in screening 
asymptomatic adults. Joanna Briggs Institute (JBI) returned 38 articles matching the 
search terms that were entered. Analytical analysis of the evidence yielded one 
evidence summary relevant to the EBP project. This evidence summary demonstrated a 
high level of quality evidence. Many of the evidence summaries were more applicable to 
interventions of identified cardiovascular risk factors rather than the role of risk factors in 
the development of cardiovascular disease. Albeit valuable evidence, this EBP project 
focus was on identifying cardiovascular risk factors rather than focusing on interventions 
to change the trajectory of the significance of the risk factor as it relates to CVD 
development. A search of the Cochrane database returned a total of 82 potentially useful 
articles of high level evidence. A multitudinous number of these were focused on 
interventions rather than on risk assessment screening. After critical review of the 
abstracts and sifting through the research, three high quality evidence articles were 
included in the appraisal of relevant literature. PubMed resulted in a consequential 
number of applicable evidence. Using the identified search terms, 139 results were 
returned. Assessing the evidence culminated in five usable articles. Systematic reviews 
of risk prediction model comparisons along with systematic review of cardiovascular risk 
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factors were gleaned and found applicable to the EBP project. Google Scholar yielded a 
plethora of hits and was very onerous to narrow the search to relevant evidence for the 
EBP project. This search engine was a source of frustration as attempts at narrowing 
search terms still apportioned an abundance of potential research, but many did not 
match the defined criteria for the EBP project. After reviewing the returned abstracts, 
three articles were found to meet inclusion criteria and deemed appropriate for the EBP 
project. The National Guideline Clearinghouse search criteria resulted in 87 potentially 
appropriate articles. Analyzing the guidelines and articles resulted in four germane 
guidelines and articles appropriate for the EBP project. MEDLINE search terms accrued 
an initial 4104 results that matched the search parameters. Further narrowing of criteria 
resulted in a total of 47 articles that were reviewed and evaluated which terminated in 
two articles for integration into the appraised evidence. Once the evidence was 
amalgamated, hand searching was completed for any supplementary pertinent research.   
Levels of evidence  
The evidence was evaluated and categorized based on the hierarchy of evidence 
pyramid delineated by Melnyk and Fineout-Overholt (2011). These levels of evidence 
range from I, the highest level of evidence to VII, the lowest level of evidence. These 
levels of evidence are connoted in the note to Table 1.1 which provides summaries 
inclusive of author(s), date and type of study, study design, outcomes and relevance to 
the EBP project and clinical practice. 
 The levels of evidence from the 20 included research articles ranged from Level I 
to Level VI. Included in the appraised evidence were 14 Level I systematic reviews or 
clinical guidelines, four Level IV which included two case control studies and two cohort 
studies, and two Level VI studies, one which was a single descriptive study and one that 
was a cross sectional study.  Clinical practice guidelines were appraised using the 
Appraisal of Guidelines for Research & Evaluation (AGREE II) and all other research 
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was appraised using the Critical Appraisal Skills Programme (CASP). The appraisal of 
current relevant research yielded a significant number of high levels of evidence.   
Appraisal of relevant evidence 
A total of 20 articles were included in the appraisal of evidence and are 
summarized in Table 1.1. An examination of this evidence will be discussed in greater 
detail in the following section. 
Table 1.1 Levels of Evidence 
Author(s)             Level of evidence   Study design      Outcomes             Implications___ 
Siontis et al. 2012 
Comparisons of 
established risk 
prediction models 
for cardiovascular 
disease: systematic 
review 
 
 
 
 
 
 
 
 
 
 
 
Matheny et al., 2011 
Systematic review of 
cardiovascular risk 
assessment tools  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hsu, et al., 2013  
A clinician’s guide to 
the ABC’s of 
cardiovascular 
disease prevention: 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level IV Case 
Control 
 
 
 
Comparative 
predictive model 
studies included 56 
pairwise comparisons 
of 8 cardiovascular 
prediction models. 
Medline and citation 
search of studies 
compared at least 2 
major risk models in 
the general 
population. 
 
 
 
 
 
 
Comparison of 
externally and 
internally validated 
risk prediction 
models that included 
prospective and 
randomized 
controlled trials. 
Study designs were 
accepted if 
evaluation was of 
asymptomatic 
patients. Medline 
search from 1999-
2009 and reference 
searching was done. 
 
INTERHEART case 
control study 
comparing the FRS 
model and RRS 
model 
One model was no 
better than another 
in cardiovascular 
disease risk 
stratification. 
Limitations included 
same geographic 
areas, same study 
population 
(European), no 
language restriction, 
sample size or 
duration limits.  
 
 
 
 
 
The objective the 
USPSTF sought to 
determine was if a 
specific model 
performed better 
and therefore would 
be more applicable in 
a primary care 
setting. The FRS 
models performed 
well in the U.S. 
population, the 
newer models being 
more predictive than 
older models.  
 
 
Comparison of the 
FRS and the RRS 
model in 9 
modifiable risk 
factors. The RRS 
Clinical usefulness of 
the various models is 
based on their 
potential for 
affecting decisions 
on treatment and 
prevention and 
improving health 
outcomes. The FRS 
model was 
compared in 50/56 
pairwise 
comparisons, the 
reliability and validity 
of the model had 
previously been 
validated. 
 
Evidence supports 
use of the FRS in a 
primary care setting. 
It has been 
compared to global 
models and has 
performed 
successfully in the 
U.S. population. This 
tool will be 
applicable for this 
DNP project 
manager to apply to 
the EBP project study 
population. 
 
 
The RRS assessment 
adds family history 
and CRP-hs to the 
FRS which 
demonstrated more 
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The John Hopkins 
Ciccarone Center for 
the prevention of 
heart disease and 
the American 
College of 
Cardiology 
cardiosource 
approach to the 
million heart’s 
initiative 
 
 
 
 
Cooney et al., 2010 
Cardiovascular risk 
estimation systems 
in primary 
prevention: Do they 
differ? Do they 
make a difference? 
Can we see the 
future? 
 
 
 
 
 
 
 
 
 
 
Mosca et al., 2011 
Effectiveness-based 
guidelines for the 
prevention of 
cardiovascular 
disease in women- 
2011 update: A 
guideline from the 
American Heart 
Association   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RCT’s comparing risk 
models focusing on 
rationale for 
estimating 
cardiovascular risk, 
comparison of 
current models for 
reliability and 
validity, and whether 
evidence exists that 
cardiovascular risk 
estimation improves 
patient outcomes. 
 
 
 
 
 
 
Review of RCT’s and 
prospective cohort 
studies that included 
greater than 1000 
women. This was a 
follow-up to the 2007 
guideline. PubMed, 
Embase, and 
Cochrane were 
searched using the 
date ranges of 2006-
2010. 
 
 
 
 
 
 
 
 
 
 
 
 
model includes 
family history and 
CRP-hs. When 
applied to 25,000 
asymptomatic 
women identified as 
low risk by the FRS, 
40% were reclassified 
at a higher risk when 
the RRS was applied.  
 
 
 
 
 
The rationale for 
implementation of 
risk modeling is that 
CVD is the result of 
combined effect of 
several risk factors. 
Patients identified 
with high risk who 
are randomized to 
interventions have 
shown greater 
reduction in risk 
factor levels and 
decreased 
cardiovascular 
disease. 
 
 
 
There were 
significant changes 
from the 2007 
guidelines. 
Effectiveness of 
prevention therapies 
was added to the 
previous guidelines. 
It was demonstrated 
that preventiom 
strategies were 
shown to have 
sufficient evidence 
and clinical benefit in 
regard to CVD 
outcomes. An 
algorithm was 
established for the 
evaluation of CVD 
risk. 
 
 
 
 
women were 
stratified to a higher 
risk level. CRP-hs is a 
costly laboratory test 
that may not be 
applicable to use in 
the OB/GYN practice 
setting. One of the 
goals of risk 
assessment 
screening is to make 
it readily available 
and easy to apply to 
the identified cohort.  
 
The FRS model was 
identified as the best 
known nationally 
and internationally 
and the most 
commonly used risk 
prediction model. To 
be used clinically, the 
risk model must be 
methodical, robust, 
easy to use, and be 
able to detect 
clinically relevant risk 
factors. The FRS 
model meets these 
criteria and will be 
applicable in the EBP 
project site. 
 
This systematic 
review was 
particularly 
applicable to the EBP 
implementation site 
as it succinctly 
discussed barriers to 
screening in this 
clinical setting. The 
authors also 
delineated 
disparities in CVD 
screening and 
interventions. The 
authors discussed 
the imperativeness 
of screening younger 
women (ages 35-54) 
which is similar to 
the inclusion criteria 
age range for this 
DNP EBP project. 
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Perk et al., 2012 
European guidelines 
on cardiovascular 
disease prevention 
in clinical practice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colagluri et al., 2009 
Guidelines for the 
assessment of 
absolute 
cardiovascular risk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dykova, M., Drew, 
C., Wright, N., 
Clarke, A., & Rees, K. 
2013 Systematic 
versus opportunistic 
Level I Clinical 
Practice Guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I National 
Guideline 
Clearinghouse 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Review of 
RCT’s 
 
 
 
The Joint Taskforce 
of the European 
Society of Cardiology 
along with eight 
other societies who 
focus on CVD 
prevention reviewed 
current levels of 
evidence and 
recommendation 
from RCT’s and 
systematic reviews to 
create current 
practice guidelines. 
Evidence was 
analyzed on the 
GRADE criteria to 
establish quality of 
evidence and 
strength of 
recommendation. 
 
Data base search of 
Australasian Medical 
Index, CINAHL, 
Cochrane database, 
EMBASE, EBM 
(OVID), and Medline 
including systematic 
reviews and RCT’s 
that compared the 
predictive ability of 
different methods of 
risk assessment. A 
total of 20,991 
studies were 
narrowed down to 30 
studies that met 
inclusion criteria. 
Among the clinical 
questions to be 
answered in the 
guideline was to 
determine which risk 
assessment method 
is most predictive of 
future CVD events in 
a mixed adult 
population without a 
diagnosis of CVD.  
 
 
 
The primary 
objective of this 
review was to assess 
the effectiveness, 
costs, and adverse 
In apparently healthy 
persons, CVD risk is 
most frequently the 
result of multiple 
interacting factors. 
Good clinical 
guidelines are a 
major mechanism to 
improving the 
delivery of 
healthcare and 
improving patient 
outcomes. 50% of 
reductions seen in 
CVD mortality are 
related to changes in 
risk factors. 
 
 
 
 
 
Modeling studies 
were appraised and 
it was found that the 
most cost-effective 
strategies for 
preventing CVD are 
those that direct 
intervention 
strategies on CVD 
risk assessment 
rather than targeting 
on individual risk 
factors in isolation. 
The highest level 
recommendation in 
the guideline is that 
absolute CVD risk 
assessment, using 
the FRS equation to 
predict risk of a 
cardiovascular event 
of the next 5 years 
should be performed 
on all adults between 
the ages of 45-74 
who are known to 
not have CVD. 
 
 
 
 
A standard 
assessment based on 
simple questions and 
measurements 
would be effective in 
The evidence 
supports the need 
for assessment of 
CVD risk factors in 
the clinical practice 
setting. Assessment 
of risk and 
intervention is 
significant in 
reducing CVD 
mortality and 
improving health 
outcomes in the 
general population. 
The European 
consensus supports 
the necessity of 
screening 
asymptomatic 
patients. 
 
 
Modeling studies 
provide compelling 
current evidence 
that CVD risk 
assessment in 
general practice is 
likely to improve 
CVD outcomes and 
direct 
patient/clinician 
decision-making on 
risk reduction 
strategies. These 
guidelines 
recommend the FRS 
tool as the initial 
assessment tool to 
ascertain CVD risk in 
asymptomatic 
patients. The FRS 
assessment tool is 
the identified tool 
for use in this DNP 
EBP project. The FRS 
model was chosen 
for its reliability and 
validity and its ease 
of use in the clinical 
practice 
environment. 
 
This Cochrane review 
is most applicable to 
this DNP EBP project 
as the methodology 
for implementation 
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risk assessment for 
the primary 
prevention of 
cardiovascular 
disease. The 
Cochrane 
Collaboration 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Greenland et al., 
2010  
ACCF/AHA guideline 
for assessment of 
cardiovascular risk in 
asymptomatic adults 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Clinical 
Practice Guidelines  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
effects of systematic 
risk assessment 
compared to 
opportunistic risk 
assessment for the 
primary prevention 
of CVD. RCT’s 
included individuals 
without diagnosis of 
CVD. The two types 
of interventions 
appraised included 
systematic risk 
assessment for 
primary prevention 
of CVD, defined as 
screening involving a 
pre-determined 
selection process 
where asymptomatic 
individuals 
systematically 
received risk 
assessment and 
opportunistic risk 
assessment 
screening which 
occurs sporadically 
and without 
identified guidelines. 
 
Rigorous search of 
the evidence was 
done and guideline 
recommendations 
were prioritized 
based on the type of 
studies that were 
done. Level A 
recommendations 
were based on data 
derived from 
multiple RCT’s or 
meta-analyses. Level 
B data was derived 
from single RCT or 
nonrandomized 
studies. Evidence was 
ranked as C when the 
primary source was 
consensus opinion, 
case studies, or 
standard of care. 
These guidelines are 
specific to 
populations residing 
in North America. 
 
identifying CVD risk 
in asymptomatic 
individuals. 
Systematic risk 
assessment was 
deemed to be more 
effective in 
identifying levels of 
risk and was more 
cost effective than 
opportunistic 
assessment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The guidelines are 
intended to assist 
health care providers 
in clinical decision 
making. The 
guidelines attempt to 
define practices that 
meet the needs of 
most patients in 
most situations 
making them 
generalizable to a 
myriad of practice 
settings. The goal of 
early assessment of 
CVD risk is to provide 
a foundation for 
targeted preventive 
efforts based on that 
individual’s predicted 
risk. The guideline 
proves an evidence-
based approach to 
risk assessment. The 
first 
recommendation is 
for the use of global 
will be a systematic 
approach versus an 
opportunistic 
method. 
Opportunistic 
assessment would 
miss a large 
percentage of 
individuals who are 
not being screened 
for CVD risk. This 
practice setting 
currently has no 
standardized tool or 
method to screen 
women for CVD risk. 
Opportunistic 
assessment would be 
disorganized, 
disjointed, and 
would not address 
the health needs of 
the identified 
population nor 
accurately assess for 
CVD risk.  
 
 
 
 
 
Guidelines that are 
generalizable in a 
myriad of practice 
settings provide data 
that has enhanced 
reliability and 
validity. These 
practice guidelines 
are entrenched with 
high levels of 
evidence. These 
guidelines are 
applicable to this 
DNP EBP project as 
they focus on an 
initial assessment of 
risk in asymptomatic 
or apparently 
healthy adults. 
Another applicable 
delineation of the 
guideline is that 
there is no specific 
identified age when 
risk assessment 
should be 
completed. The 
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Worrall-Carter, L., 
Ski, C., Scruth, E., 
Campbell, M., & 
Page, K. 2011  
Systematic review of 
cardiovascular 
disease in women: 
Assessing the risk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Read, S. 2010 
Cardiovascular 
disease: Risk 
estimation and 
prevention. The 
Joanna Briggs 
Institute 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A search of the 
published literature 
was done for the 
time period of 
January 1999-June 
2011. PubMed, 
CINAHL, Embase, 
PsychINFO, and 
Medline were among 
the search engines. 
58 papers were 
critically appraised. 
Inclusion criteria 
were studies using 
meta-analyses, 
systematic reviews, 
and literature 
reviews. 
 
 
 
 
 
 
 
This evidence 
summary is based on 
a structured search 
of the literature 
using evidence-based 
health care data 
bases. Studies 
included for appraisal 
consisted of RCT’s, 
prospective cohort 
studies, and one 
nested case-control 
study. 
 
risk scores, such as 
the FRS that 
evaluates multiple 
cardiovascular risk 
factors to assess all 
asymptomatic adults 
without clinical 
history of 
cardiovascular 
disease. 
 
 
 
 
 
 
 
 
 
The FRS assessment 
was identified as a 
consistent tool that 
contributes to 
understanding CVD 
risk factors. 
Modifiable risk 
factors such as 
hypertension, 
dyslipidemia, 
inactivity, BMI, 
smoking, and 
nutrition continue to 
be consistently 
identified in the 
literature. Focus 
must be on 
identification of 
these risk factors so 
that interventions 
can be initiated, 
hopefully changing 
the course of CVD 
progression. 
 
The clinical question 
was: what are the 
significant risk 
factors related to the 
prevention or 
reduction of risk of 
CVD among adult 
populations? Best 
practice 
recommendations 
for modifiable risk 
factors were graded 
and supported by 
current evidence. 
recommendation 
states that risk 
identification can be 
done at any age even 
beginning in children 
or adolescents. This 
is pertinent as some 
guidelines 
recommend 
screening women 
beginning at age 50 
which may be too 
late to initiate 
primary prevention 
practices. The 
identified age range 
for this EBP project is 
35-50. 
 
In research 
endeavors women 
have traditionally 
been excluded or 
under represented. 
Many CVD risk 
prediction factors 
are modifiable; the 
key is effective and 
relevant risk factor 
identification. The 
FRS model has been 
assessed for validity 
and reliability and 
has historically 
performed well in 
the U.S. population. 
This tool will be the 
assessment tool in 
the EBP project. 
 
 
 
 
 
This systematic 
review continues to 
validate the 
necessity for 
screening 
asymptomatic 
individuals for 
modifiable CVD risk 
factors. Risk factors 
should be identified 
and stratified for 
comprehensive 
assessment of risk. 
The FRS model does 
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Murphy, T., 
Dhangana, R., 
Pencina, M., Zafar, 
A., & D’Agostino, R. 
2011  
Performance of 
current guidelines 
for coronary heart 
disease prevention: 
Optimal use of the 
Framingham- based 
risk assessment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
McGorrian et al., 
2011  
Estimating 
modifiable coronary 
heart disease risk in 
multiple regions of 
the world: The 
INTERHEART 
modifiable risk score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level IV Cohort 
Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level IV Case 
Control Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study was a 
retrospective analysis 
of two prospective 
cohort studies. The 
Atherosclerosis Risk 
in Communities and 
the Cardiovascular 
Health Study 
included 11,436 and 
2569 participants 
respectively. These 
individuals were 
without CVD or 
diabetes at baseline. 
The FRS variables 
were analyzed. 
Receiver Operating 
Characteristics (ROC) 
curves, sensitivity, 
specificity, accuracy, 
and other test 
performance 
characteristics were 
determined at 
various 10 year risk 
thresholds. 
 
 
 
 
 
 
Multiple logistic 
regressions were 
used to create the 
INTERHEART 
modifiable risk score 
(IHMRS). Internal and 
external validation 
was completed. 
N=19470 were 
evaluated from the 
case control study 
assessing nine 
modifiable risk 
factors with MI being 
The modifiable risk 
factors articulated 
included smoking, 
hypertension, 
dyslipidemia, 
inactivity, alcohol 
consumption, dietary 
fats, and 
recommendations on 
fruit/vegetable 
intake. 
 
The FRS was 
significantly 
associated with 
coronary heart 
disease. 10 year 
incidence rates for 
hard coronary heart 
disease such as MI or 
stroke strongly 
correlates with FRS 
categories. The 
incidence rates were 
higher in the 
Cardiovascular 
Health Study most 
likely due to an older 
population. The 
authors observed 
that the limitations in 
risk prediction were 
not in the correlation 
of the risk prediction 
algorithm with 
subsequent events, 
which demonstrated 
good correlation 
across risk 
categories, but in the 
threshold that is used 
to dichotomously 
determine high risk. 
 
Results were 
consistent across 
ethnic groups and 
geographic locales. 
Nine modifiable risk 
factors were 
predictive in 
determining risk for 
MI. These risk factors 
included 
apolipoprotein levels, 
smoking, blood 
pressure, diabetes, 
abdominal obesity, 
not specifically 
assess dietary intake 
or physical activity 
but can be 
correlated with BMI, 
waist circumference, 
and laboratory 
testing. 
 
 
 
 
Current guidelines 
recommend 
Framingham risk 
scoring to be used to 
categorize risk and to 
plan evidence-based 
interventions. 
Identification and 
intervention can 
reduce negative 
outcomes and 
reduce health care 
costs. The 
Cardiovascular 
Health Study was 
conducted in an 
older population 
which makes it less 
generalizable to the 
cohort in the EBP 
project. The 
Atherosclerosis Risk 
in Communities 
included white and 
African American 
men and women 
between the ages of 
45-64 which is more 
applicable to the age 
range of the EBP 
project. 
 
Risk stratification is 
suggested as best 
practice for the 
management of 
individual CVD risk. 
Risk assessment 
tools have 
demonstrated 
accuracy in 
determining risk. 
This tool would be 
more cumbersome 
in the clinical 
practice setting as 
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Tattersall, M., 
Gangnon, R., 
Karmali, K., & Keevil, 
J. 2012 
 Women up, men 
down: The clinical 
impact of replacing 
the Framingham risk 
score with the 
Reynolds risk score 
in the United States 
population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level VI Evidence 
from a single 
descriptive or 
qualitative study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the end point. 
Participants were 
from 52 different 
countries. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Using the National 
Health and Nutrition 
Examination Surveys 
(NHANES) the FRS 
and the Reynolds risk 
score (RRS) was 
applied to 2,502 
individuals who were 
free from CVD. The 
RRS has additional 
risk assessment 
variables in addition 
to the variables 
assessed by the FRS. 
The RRS includes 
hemoglobin A1C and 
CRP-hs which are not 
included in the FRS. 
 
 
 
 
 
 
 
 
 
 
 
 
psychological factors, 
dietary factors, 
physical exercise, and 
alcohol consumption. 
The INTERHEART 
case control study 
demonstrated that 
these nine modifiable 
risk factors account 
for 90% of the 
population 
attributable risk for 
MI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compared to the 
FRS, the RRS assigns 
a higher risk category 
to 13.9% of the 
women and a lower 
risk score to 2% of 
the women that 
were evaluated in 
the study. In the U.S. 
population, the RRS 
assigns a new risk 
category in one of 
every six women. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
some of the risk 
factors are subjective 
in nature versus 
objective and it 
would be time 
prohibitive to 
ascertain some of 
the subjective 
variables. Degree of 
second hand smoke 
exposure, definitions 
of stress, depression 
and anxiety would be 
difficult to measure. 
Use of the 
Framingham risk tool 
provides objective 
data that is 
standardized and 
would lend itself to 
statistical analysis. A 
multivariate risk 
prediction tool 
gleans data that 
identifies and 
stratifies levels of 
CVD risk.   
 
Clinician use of CVD 
risk stratification 
results in evidence-
based interventions 
and potential 
reduction in CVD 
burden. Risk models 
differ in variables, 
definition of end 
points, and the 
population in which 
they were developed 
and validated. 
Guidelines for best 
practice recommend 
routine screening for 
CVD risk in 
asymptomatic 
individuals. This DNP 
project will 
implement the FRS in 
asymptomatic 
women in an 
OB/GYN setting. Ease 
of use of a validated 
tool is going to be 
most imperative in 
initial screening for 
this cohort and this 
practice setting. 
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Katsiki, N., 
Papadopoulou, S.K., 
Fachantidou, A.I., & 
Mikhailidis, D.P. 
2013 
 Smoking and 
vascular risk: Are all 
forms of smoking 
harmful to all types 
of vascular disease?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Al-Ansary et al., 
2013 
 A systematic review 
of recent clinical 
practice guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medline was 
searched for relevant 
publications using 
keywords related to 
smoking and CVD, 
risk, primary and 
secondary 
prevention. The most 
recent evidence was 
reported. All forms of 
smoking including 
cannabis, cigar, pipe, 
smokeless tobacco, 
and cigarette 
smoking were 
evaluated in the 
study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medline, EMBASE, 
guideline websites, 
and Google were 
searched for clinical 
practice guidelines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Although all forms of 
smoking were 
associated with an 
increased risk for 
CVD, cigarette 
smoking garnered 
the highest risk and is 
the variable assessed 
by the FRS model. 
Acute active as well 
as passive smoking 
increases CVD 
morbidity and 
mortality. A 
Cochrane systematic 
review found that 
smoking cessation 
was associated with a 
significant reduction 
in the risk of all-
cause mortality 
related to CVD. 
Smoking also 
interacts with several 
vascular risk factors 
such as hypertension, 
diabetes, 
dyslipidemia, and 
homeostasis which 
further amplify CV 
risk. 
 
 
 
 
 
A large systematic 
review of 147 trial 
reports on the 
management of 
hypertension has 
Although the RRS 
reclassifies many 
women into a higher 
risk category, the FRS 
is a validated reliable 
tool to use as a 
primary prevention 
intervention. Cost 
consideration must 
be considered when 
expecting patients to 
complete laboratory 
testing as CRP-hs and 
Hgb A1C are not 
considered initial 
screening labs. 
 
Smoking is a 
significant 
modifiable risk factor 
for the development 
of CVD. In addition 
to smoking being an 
independent risk 
factor, it acts 
synergistically to 
amplify risk when 
combined with other 
risk factors. The FRS 
does assess for 
smoking status. The 
U.S. surgeon general 
has articulated 
smoking as being the 
single greatest cause 
of avoidable 
morbidity and 
mortality in the U.S. 
Smoking is dose 
related but cessation 
of smoking allows 
rapid approach to 
CVD risk of never 
smokers. As 
clinicians, it is 
imperative to 
evaluate for smoking 
history and to 
incorporate 
interventions for 
smoking cessation in 
the practice setting. 
 
All CPG’s 
recommend 
assessing for 
hypertension in 
relation to other CVD 
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on the diagnosis, 
assessment, and 
management of 
hypertension 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mohebi, R., 
Bozorgmanesh, M., 
Azizi, F., & Hadaegh, 
F. 2013 
 Effects of obesity on 
the impact of short-
term changes in 
anthropometric 
measurements on 
coronary heart 
disease in women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level IV Prospective 
Cohort Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(CPG) written in 
English between 
2006-2011. The 
search strategy 
yielded 2168 
citations of which 
114 were considered 
and 11 were 
included. The CPG’s 
were evaluated using 
the AGREE-II 
instrument.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This prospective 
design consisted of a 
sample of 2468 
women over the age 
of 30 without a 
diagnosis of CVD. 
This was sample was 
followed for a period 
of 6.6 years (mean). 
Cox proportional 
hazard regression 
was performed to 
estimate the hazard 
ratios of 
anthropometric 
measures for 
cardiovascular 
events. 
 
 
 
 
 
 
 
 
 
 
 
shown that a mere 
reduction in 10 mm 
Hg in systolic blood 
pressure and 5 mm 
Hg in diastolic blood 
pressure was 
associated with a 
20% reduction in 
coronary heart 
disease and a 32% 
reduction in stroke in 
one year. The 
continuous and linear 
relationship between 
systolic blood 
pressure and 
coronary risk is true 
for both men and 
women. 
 
 
 
 
 
 
 
 
 
 
During the follow up 
period, 5.1% of the 
participants 
exhibited a CV event. 
There was a 
significant interaction 
between BMI and 
anthropometric 
changes in prediction 
of CV events (p< .04). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
risk factors during 
patient assessment. 
Blood pressure 
measurement is one 
of the variables 
assessed with the 
FRS. Measurement 
of blood pressure is 
clinically relevant as 
population 
attributable risk 
methods suggest 
approximately 54% 
of all strokes and 
47% of all ischemic 
heart disease is 
attributable to high 
blood pressure, 
resulting in 7.6 
million annual 
premature deaths 
worldwide. Modest 
reductions in blood 
pressure 
measurements 
results in significant 
reductions in CVD 
risk. 
 
Obesity, defined as a 
BMI ≥ 30 kg/m² is a 
conventional risk 
factor for CVD. 68% 
of Americans are 
now considered to 
be overweight or 
obese. According to 
these authors, 
obesity is the leading 
modifiable risk factor 
for the development 
of CVD in women. 
Screening is simple in 
the clinical setting, 
especially for 
practices that use 
the EMR as BMI is 
automatically 
calculated for you. 
There is a dearth of 
information on 
clinicians not 
addressing this 
modifiable risk factor 
in the clinical setting. 
However, obesity 
accounted for $147 
billion in health 
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Prospective Studies 
Collaboration  2009 
Body-mass index 
and cause-specific 
mortality in 900,000 
adults: Collaborative 
analysis of 57 
prospective studies  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ip, S., Lichtenstein, 
A., Chung, M., Lau, 
J., & Balk, E. 2009 
Systematic review: 
Association of low-
density lipoprotein 
subfractions with 
cardiovascular 
outcomes  
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level I Systematic 
Review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collaborative analysis 
was undertaken of 
baseline BMI versus 
mortality in 57 
prospective studies 
in western Europe 
and North America. 
The analyses were 
adjusted for age, 
gender, smoking, and 
study design. The 
first five years of 
follow up were 
excluded, using an 
additional eight years 
of follow up analysis.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data sources 
included Medline, 
CAB abstracts, and 
Cochrane central 
register of controlled 
trials. Inclusion 
criteria were 
longitudinal studies 
that reported an 
association between 
LDL subfractions and 
 
 
 
 
 
 
 
 
 
 
 
Mortality was lowest 
in patients with BMI 
levels of 22.5-25 
kg/m². Each 
additional 5 kg/m² 
BMI was on average 
associated with an 
increased 30% 
overall mortality 
rate, 40% associated 
with increased CV 
mortality. At 30-35 
kg/m² median 
survival is reduced by 
2-4 years and at 40-
45 kg/m² median 
survival from a CV 
event is reduced by 
8-10 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Higher LDL particle 
number was 
consistently 
associated with 
increased risk for 
CVD, independent of 
other lipid 
measurements. 
Studies have not 
determined whether 
any measures of LDL 
spending in 2008 and 
is expected to rise to 
$244 billion per year 
by 2018. The FRS 
model has a separate 
data base that 
assesses CVD risk 
that is  based on BMI 
and other non-
laboratory variables. 
 
Increased prevalence 
of BMI ≥25 kg/m² 
has been 
consistently 
increasing over the 
years. Obesity is now 
being observed in 
childhood and 
adolescence. There 
have not been 
studies following 
childhood obesity 
into adulthood for its 
effect on morbidity 
and mortality. This 
modifiable risk factor 
has a strong 
associative effect on 
the development of 
CVD. The Nurse’s 
Health Study 
demonstrated that 
women who gained 
more than 25 
pounds in weight 
had a five-fold 
increase for the risk 
of hypertension. 
Obesity plays an 
increased CV risk in 
multiple variables 
such as 
hypertension, 
dyslipidemia and 
Type II diabetes.  
 
The ATP-III of the 
Expert Panel of the 
National Cholesterol 
Education Program 
has identified 
elevated LDL 
cholesterol as 
pervasive CVD risk 
factor. LDL 
subfractions are a 
myriad of additional 
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Kim, J., Sillah, A., 
Boucher, J., 
Sidebottom, A., & 
Snickelbine, T. 2013 
Prevalence of the 
American Heart 
Association’s “ideal 
cardiovascular 
health” metrics in a 
rural, cross-
sectional, 
community-based 
study: The heart of 
New Ulm project   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Level VI Cross 
Sectional Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
incidence of CVD. 
Data was extracted 
from 24 studies 
which were 
homogeneous in 
terms of specific 
tests analyzed, 
analytical methods, 
participants, and 
outcome measures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sample size 
consisted of 4754 
adults in New Ulm, 
Minnesota that 
participated in 
community heart 
health screenings in 
2009 or 2011. 58.3% 
of the participants 
were women. Data 
collected at the 
screenings were 
analyzed to replicate 
the AHA ideal 
cardiovascular health 
measure. There were 
seven metrics that 
were evaluated: 
smoking status, BMI, 
nutrition, physical 
activity, blood 
pressure, blood 
glucose, and 
cholesterol panel. 
subfractions add 
incremental benefit 
to traditional risk 
factor assessment. 
There is limited data 
from cross-sectional 
and prospective 
studies that further 
analysis of LDL 
cholesterol is a 
better discriminator 
of CVD risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only 1% of the 
participants met the 
AHA’s definition of 
ideal CV health in all 
seven metrics. This 
cross sectional design 
had similar results to 
other published 
studies and appears 
to be representative 
of the U.S. 
population.  
 
 
 
 
 
 
tests what are 
typically not covered 
by insurance, 
especially as initial 
screening carried out 
in the primary care 
setting. The 
recommended 
screening continues 
to be total 
cholesterol, LDL, 
HDL, and triglyceride 
levels. This is the 
lipid assessment that 
will be run as part of 
the EBP project. 
Future research may 
find LDL subfractions 
as having greater 
specificity for CVD 
risk but the NCEP 
guideline 
recommendation 
continues to be the 
standard lipid panel. 
 
These seven AHA 
metrics are 
significant for 
evaluation of CV 
health in the clinical 
practice setting. It 
has been reiterated 
time and again that 
CVD is multi-factorial 
in nature. There is an 
additive negative 
consequence with 
multiple risk factors. 
It is imperative for 
the practicing 
clinician to apply a 
validated CV risk 
prediction tool in 
asymptomatic adults 
to evaluate CVD risk. 
Achieving ideal CV 
health lowers risk for 
CVD, lowers 
mortality rates, and 
increased life 
expectancy. CVD is 
economically 
burdensome with CV 
related costs 
comprising 17% of 
the nation’s total 
health expenditures.   
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Note: Level I: Evidence from a systematic review or meta-analysis of all relevant randomized controlled trials 
(RCT), or evidence-based clinical practice; Level II: Evidence obtained from well-designed RCT’s; Level III: 
Evidence from well-designed controlled trials without randomization; Level IV: Evidence from well-designed 
case-control and cohort studies; Level V: Evidence from systematic review of descriptive and qualitative 
studies; Level VI: Evidence from single descriptive or qualitative studies; Level VII: Evidence from opinion of 
authorities and/or reports of expert committees (Melnyk & Fineout-Overholt, 2011, p. 12) 
Siontis, Tzoulaki, Siontis, & Ioannidis, (2012) compared cardiovascular disease 
risk prediction models on their accuracy for prognostic prediction. Studies were included 
that compared at least two different prediction models applied to the general population. 
A total of eight risk prediction models were assessed for validity, reliability, and accurate 
prognostic performance. The basis for the study was the opinion that practitioners need 
reliable multivariate CVD risk assessment tools that can easily be utilized in the clinical 
setting. Albeit limitations to the study were elucidated, the conclusion was that there was 
no one risk prediction tool that was superior to another. The clinical usefulness of a risk 
prediction model is its potential for affecting health care decision making and improving 
health outcomes (Siontis, Tzoulaki, Siontis, & Ioannidis, 2012). 
 The Agency for Healthcare Research and Quality (Matheny, McPheeters, 
Glasser, Mercaldo, Weaver, Jerome, Walden et al., 2011) completed a systematic 
review of current CVD risk assessment tools applied in U.S. populations. The initial 
search resulted in identification of 102 various risk models, however, 87 of these models 
lacked validation. Of the remaining models assessed, the Framingham Risk Score 
(FRS), Prospective Cardiovascular Münster (PROCAM), and the Systematic Coronary 
Risk Evaluation (SCORE) were the tools most commonly reported in the literature. The 
objective of the review was to assess risk models for the best prediction of 
cardiovascular risk. The conclusion was that the FRS models performed well in U.S. 
populations but concerns were raised regarding generalizability of the tool to diverse 
populations. It was observed that when the FRS model was applied to a population that 
was different from the original cohort, the risk prediction scores were not consistent. It 
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was concluded that the newer models of the FRS performed better than the older 
models and the gender specific models provided greater reliability. Additionally, all risk 
prediction models demonstrated good relative and absolute risk prediction in the cohort 
in which they were developed bringing into question the limitations of every risk 
prediction model. Overall, the FRS models were deemed to be valid and reliable and a 
favorable tool to use in clinical practice. 
 Hsu, Van-Khue, Ashen, Martin, Gluckman, Hohli, Sisson, Blumenthal & Blaha 
(2013) in conjunction with John’s Hopkins and the American College of Cardiology 
evaluated a global case control study entitled the INTERHEART Study, evaluating CVD 
risk factors and creating an easy acronym to assist practitioners in clinical practice. This 
Level IV evidence evaluated nine modifiable risk factors that are associated with >90% 
of the risk for a first myocardial infarction (MI). The ABCDE approach which stands for 
assessment of risk, antiplatelet therapy, blood pressure, cholesterol, cigarette smoking, 
diet and weight, and exercise provides a guide for a consistent comprehensive approach 
to cardiovascular risk assessment. This approach and recommendations which are 
supported by evidence, provides a core framework for addressing CVD risk with the goal 
of preventing CVD. The authors articulated the FRS model as being the most commonly 
used global risk assessment tool. The authors did elucidate however, that in some 
populations risk was underestimated by the FRS model. The authors compared the FRS 
model with the Reynolds risk prediction tool. The Reynolds risk assessment adds family 
history and CRP-hs data in its prediction model which are not included in the FRS 
model. Application of the Reynolds risk score in the female population often reclassifies 
their risk status to a higher level when compared to the FRS model. Ease of use in the 
clinical setting and its consistent validation of reliability and validity still make the FRS 
model an appropriate choice for CVD risk prediction. Cost considerations versus 
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additional value of biomedical markers must be contemplated when initiating CVD risk 
screening.  
 Cooney, Dudina, D’Agostino, & Graham (2010) in their systematic review 
attempted to determine if CVD risk prediction as a primary prevention measure makes a 
difference in clinical practice. The authors sought to appraise the evidence for the 
rationale of estimating cardiovascular risk, compare the current CVD risk models for 
clinical applicability, seek evidence for estimating CVD risk related to patient outcomes, 
and determine the direction of CVD risk prediction in the future. According the authors, 
to be clinically useful a CVD risk estimation model should be methodologically robust 
and easy to use as well as address clinically relevant risk factors. A noted universal 
limitation of all risk prediction models is the assumption that the effect of the risk is 
constant, not taking into consideration age and level of degree of each of the identified 
risk factors.  
 The authors assessed various risk prediction models for internal and external 
validation as well as calibration. Calibration metrics for predicted to observed ratios 
indicate values closest to one as being the best fit. Values >1 indicate overestimation 
and values <1 indicative of underestimation. In a number of research studies, the FRS 
models demonstrated calibration values between 0.76-0.86 (Cooney, Dudina, 
D’Agnostino, & Graham, 2010). The FRS models have been modified over the years and 
continue to be the most widely accepted and utilized models both nationally and 
internationally. The FRS model remains the recommended assessment tool in both 
national and international CVD prevention clinical practice guidelines.  
 The authors, due to a paucity of evidence, were unable to answer whether 
identification of CVD risk makes a difference in patient outcomes. It is well agreed upon 
that CVD is a multivariable disease and it is imperative to assess total risk versus 
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identification and intervention of only single risk factors but additional research must be 
rendered to answer the question posed by the authors.    
 The systematic review by Mosca et al. (2011) focused specifically on guidelines 
for the prevention of CVD in women. The authors reviewed randomized controlled trials 
(RCT’s) based on CVD prevention in women. One of the major findings discovered in 
the review was a discerning escalation in CVD deaths in women between the ages of 
35-54. The algorithm for risk stratification recommended three categorical levels of risk: 
high risk, at risk, and optimal risk as defined by the number of CVD risk factors. Among 
high risk, at risk, and optimal risk, the rates of MI, CVD deaths or stroke were 19.0%, 
5.5% and 2.6% per ten years respectively (P for trend <0.0001) (Mosca et, al., 2011). 
 Because the lifetime risk for cardiovascular death in women is one out every two 
women, it was determined through critical analysis of the literature, that the effectiveness 
of prevention therapies did exhibit clinical benefit for improving CVD outcomes. By 
establishing scientific levels of evidence and desired treatment strategies, guidelines are 
fundamental in improving CVD preventive care. It was specified that applying evidence-
based lifestyle modifications and interventions were the most cost-effective method for 
CVD prevention.  
 The European Clinical Practice Guidelines authored by Perk et al. (2012) 
disseminated recommendations on CVD prevention that should be both individual and 
population focused. 1900 articles including RCT’s, meta-analyses, and non-randomized 
control studies on risk assessment and CVD were evaluated using the AGREE 
instrument. The guideline recommendations were rated based on the GRADE system 
and are consistent with other reviews and guidelines in regard to modifiable risk factors. 
Research supports the effectiveness of prevention strategies; 50% of reductions in CVD 
mortality are related to changes in risk factors whereas, the World Health Organization 
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(WHO) purports that greater than three-fourths of CVD mortality could be prevented by 
lifestyle changes. 
 The authors analyzed the current literature and compared the FRS model with 
the SCORE model demonstrating the estimation of risk as being comparable. A 5% 
SCORE risk equated to a 10-25% Framingham risk corroborating the similarity of 
outcomes in established risk prediction models (Perk et al., 2012). 
  It is essential for clinicians to be able to assess risk in a timely manner and with 
sufficient accuracy to allow for logical management decisions in the practice setting. 
Research and evidence-based clinical guidelines are an excellent mechanism for 
improving the delivery of healthcare and improving patient outcomes.  
 Colagiuri, Tonkin, Harris, Briffa, Huang, Cary-Harzell, Azidi, et al. (2009) 
published clinical guidelines for the assessment of absolute CVD risk. The objective of 
the guideline was to assist health care professionals in assessing CVD risk in an 
accurate manner in order to assist their patients in making well informed decisions about 
clinical care management of the identified risks. The target population included adults 
over the age of 18 without known CVD. The guideline authors sought to determine which 
absolute risk assessment method is most predictive of future CVD events in a mixed 
adult population not known to have CVD or diabetes. A search of the literature did not 
specifically analyze the cost effectiveness of one assessment model over another. It was 
reasonable to conclude, according to the authors, that there would be a realized cost 
benefit that would result from implementation of an accurate risk prediction tool in 
asymptomatic adults. The number one recommendation for intervention and practice 
was to implement the FRS model for all adults ages 45-74 who are not known to have 
CVD. Modeling studies provide the most compelling evidence that CVD risk assessment 
in general practice is likely to improve CVD outcomes, compared with assessment and 
treatment of single risk factors.  
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 Dyakova, Drew, Wright, Clarke & Rees (2013) through the Cochrane Heart 
Group developed a protocol on CVD risk assessment as a primary prevention 
intervention. The authors recommended systematic risk assessment versus 
opportunistic risk assessment. Systematic risk assessment was defined as a screening 
program that involves a pre-determined process for selection of people who are 
systematically assessed for CVD risk in a primary care or similar setting. Opportunistic 
risk assessment was defined as a CVD risk assessment occurring sporadically in a 
primary setting which could include a primary care office, pharmacy, occupational health 
department or in a small business. The review focused on the effectiveness of 
comparing systematic (intervention) to opportunistic risk assessment (control) for 
primary prevention of CVD. According to the NHS Health Checks program, a standard 
assessment based on simple questions and measurements to identify the risk of CVD, 
was deemed to be the most effective.  
 Greenland, Alpert, Beller, Benjamin, Budof, Fayad, & Foster, et al. (2010) in 
conjunction with the American College of Cardiology Foundation (ACCF) and the 
American Heart Association (AHA) published guidelines for the assessment of 
cardiovascular risk in asymptomatic adults. The guideline objectives were to assist 
healthcare practitioners in clinical decision making, to assist providers in the initial 
assessment of risk in apparently healthy adults, and to provide a foundation for targeted 
preventive efforts based on an individual’s predicted risk. These authors presented a 
paradigm of care for the standardization for CVD risk assessment in this population. The 
goal of early risk identification in asymptomatic individuals is to provide targeted 
interventions to reduce or eliminate the identified risk factors. Cardiovascular disease 
has a long asymptomatic latent period which provides an opportunity for early and 
effective preventive interventions. The recommendation by the authors was for use of a 
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global risk score, such as the FRS, that evaluates multiple traditional cardiovascular risk 
factors.  
 Worrall-Carter, Ski, Scruth, Campbell, & Page (2011) authored a systematic 
review of CVD risk in women, acknowledging the gender differences in CVD risk 
significance. Risk factor modification is paramount for primary and secondary prevention 
of CVD. Analysis of the Framingham Heart Study, of which 53% of the participants were 
female, identified six main risk factors for CVD. The risk factors purported to be most 
significant were blood pressure, lipids, smoking, diabetes, BMI, and physical inactivity. 
The authors concluded that most CVD risk in women is modifiable and the key is 
effective and relevant risk factor identification and early intervention.  
 The cardiovascular disease risk estimation and prevention summary authored by 
Read (2012) and published by JBI confirmed the maxim that CVD has multiple risk 
factors, of which the majority are modifiable. Moderate risk individuals constitute the 
largest group of screened individuals and this population also has the highest rate of 
mortality. The best practice recommendations in addition to advocating risk prediction in 
asymptomatic adults were to focus on research evidence that supports positive 
improvements in modifiable risk factors. 
 Murphy, Dhangana, Pencina, Zafar, & D’Agostino (2011) evaluated the FRS 
model for its risk prediction capabilities. The model was evaluated using Receiver 
Operating Characteristics (ROC) curves, sensitivity, specificity, and accuracy. There is a 
strong positive association between the FRS prediction and the incidence of hard 
coronary heart disease. The current Adult Treatment Panel III (ATP III) guidelines call for 
intensive medical risk factor reduction in individuals identified at moderate or high risk by 
the FRS model. There is no known trigger threshold with regard to an individual risk 
factor; therefore individual risk factor management strategies are less than optimal for 
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effectively lowering overall risk. It is imperative to implement comprehensive risk 
lowering reduction in those individuals identified with multiple CVD risk factors.  
 McGorrian, Yusuf, Islam, Jung, Rangarajan, Avezum, & Prabhakaran et al. 
(2011) applied the INTERHEART modifiable risk score to a multi-international 
population. Summating risk factor burden is crucial in assessing CVD risk in apparently 
healthy persons. As previously elucidated, the INTERHEART risk score assesses nine 
modifiable risk factors that are estimated to account for more than 90% of the population 
attributable risk. The benefit of using the INTERHEART risk score, as articulated by the 
authors, included its applicability to a number of populations and ethnically diverse 
cultures around the world. The variables assessed through this tool are time consuming, 
costly and glean a significant amount of subjective data such as stress and depression 
levels. The tool, albeit valid, would not easily be implemented into a busy clinical practice 
setting. 
 Tattersall, Gangnon, Karmali, & Keevil (2012) compared the clinical impact of 
replacing the FRS with the Reynolds Risk Score (RRS) in U.S. populations. Risk models 
differ in variables, definitions of endpoints and the population in which they were 
developed and validated. Both the FRS and the RRS have been validated in the U.S. 
population. 1440 women who were analyzed with the FRS found 82% to be at low risk, 
11.4% at moderate risk and 0.6% at high risk. In contrast, when using the RRS, risk 
classifications were more severe (p<0.0001) with 76% at low risk, 11% at moderate risk, 
9.3% at moderate-high risk, and 3% at high risk (Tattersall, Gangnon, Karmali, & Keevil, 
2012). The magnitude and direction of change were more noticeable in women than in 
men when comparing the models. In an effort to translate the differences in the models 
to clinical practice, it was found that only a small percentage of individuals who had been 
reclassified received different clinical recommendations regarding treatment of risk 
factors.  
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 Clinicians have an increasing number of choices of which cardiovascular risk 
prediction tool to utilize and how to determine the population effects of various 
multivariate risk models compared to the well accepted FRS models. A practicing 
clinician must choose a model that will be advantageous with the patient population and 
applicable to the clinical practice setting. 
 As previously elucidated, there are a handful of modifiable risk factors that 
account for 80-90% of all CVD morbidity and mortality, these modifiable CVD risk factors 
will be discussed in the following section.  
Smoking 
 Smoking both active and passive is a well-established vascular risk factor and 
one which is prima facie to modify. Katsiki, Papadopoulou, Fachantidou, & Mikhailidis 
(2013) in a narrative review, weighed the effects of various forms of smoking on CVD 
risk. Although various forms of smoking all pose a CVD risk, cigarette smoking is 
compellingly associated with morbidity and mortality. In a meta-analysis review, smoking 
cessation was shown to significantly reduce CVD mortality (OR=0.54, 95% CI=0.46-
0.62). A Cochrane systematic review found that smoking cessation was associated with 
a significant (36%, OR=0.64, 95% CI=0.58-0.71) reduction in all case mortality. Smoking 
can cause endothelial dysfunction, enhance platelet aggregation, and impair fibrinolysis, 
increasing the prevalence and severity of thrombotic CVD events. Smoking interacts 
with several other cardiovascular risk factors including hypertension, dyslipidemia, and 
diabetes to significantly augment level of risk.  
Hypertension 
 Al-Ansary, Tricco, Adi, Bawazeer, Perrier, Al-Ghanaim, Alyousefi, et al. (2013) 
completed a systematic review of recent clinical practice guidelines (CPG’s) on the 
management of hypertension. Eleven CPG’s were evaluated using the AGREE-II 
assessment tool. There was disparity among the guidelines regarding levels of 
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hypertension, when to initiate treatment, what treatment to initiate, and what the goal of 
hypertension management should be. Regardless of the disparate recommendations in 
the CPG’s, it was consistently recommended that blood pressure be assessed in 
relationship to other cardiovascular risk factors during patient assessment.  
 A large systematic review of 147 clinical trials reporting on the management of 
hypertension; showed that a mere reduction of 10 mm Hg in systolic blood pressure and 
5 mm Hg reduction in diastolic blood pressure was associated with a 20% reduction in 
coronary heart disease and 32% reduction in stroke in one year (Al-Ansary et al., 2013). 
The FRS has authenticated the associative relationship between blood pressure and 
cardiovascular risk as continuous and linear and consistent across age groups for 
development of cardiovascular events. It has been estimated that 54% of all strokes and 
47% of all ischemic heart disease is attributable to high blood pressure (Al-Ansary et al., 
2013). Despite the availability of CPG’s, optimal hypertension control remains an 
intangible goal worldwide. 
Obesity 
 Mohebi, Bozorgmanesh, Azizi, & Hadaegh (2013) assessed the effects of obesity 
on coronary heart disease in women and the Prospective Studies Collaboration (2009) 
analyzed 57 prospective studies on BMI and cause specific mortality. Epidemiologic 
studies have found obesity (BMI ≥30 mg/m²) to be a conventional risk factor for coronary 
heart disease. Cross-sectional associations between BMI and risk factors were 
estimated by multiple linear regression or logistic regression with adjustment for study, 
baseline age, and baseline smoking status. Increased BMI was associated with 
increased blood pressure and abnormal lipids which are additionally both modifiable risk 
factors for CVD. Mortality is lowest in in those individuals with an optimum BMI of 22.5-
25 kg/m². For every 5 kg/m² higher BMI, there was an associated 30% higher all-cause 
mortality (Mohebi, Bozorgmanesh, Azizi, & Hadaegh, 2013).   
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Cholesterol 
 Ip, Lichtenstein, Chung, Lau, & Balk (2009) disseminated findings on a 
systematic review evaluating the association of low-density lipoprotein with 
cardiovascular outcomes. There is irrefutable evidence that high levels of total 
cholesterol, low-density lipoprotein (LDL), and low levels of high-density lipoprotein 
(HDL) are salient risk factors for cardiovascular disease. According to the authors, LDL 
cholesterol is influential in enhancing CVD risk. LDL cholesterol is not taken up by the 
cells, staying in the blood stream and creating foam cells which causes inflammation and 
increases risk for ischemia and hypertension. It is estimated elevated cholesterol 
fractions account for greater than 50% of all cardiovascular events. Dyslipidemia is yet 
another CVD risk factor considered to be a modifiable risk factor. 
 Kim, Sillah, Boucher, Sidebottom, & Knickelbine (2013) in a cross-sectional study 
assessed for ideal cardiovascular risk in a rural community in Minnesota. The delineation 
of ideal cardiovascular risk as defined by the American Heart Association includes seven 
modifiable metrics for assessing cardiovascular health. These ideal metrics include 
blood pressure, cholesterol levels, smoking status, physical activity, BMI, dietary intake, 
and blood glucose. The researchers gathered data in a cross-sectional cohort over a 
period of two years. SPSS statistical analysis using a two-sided α considered statistical 
significance to be 0.05. Pearson x² tests were used for comparisons of age and sex. 
Attaining ideal cardiovascular health in this study was extremely low (1%), however 
achievement of ideal cardiovascular health metrics would notably decrease CVD burden 
and associated health care costs. 
Synthesis of the critically appraised literature   
Current relevant literature provides a superlative perspective of cardiovascular 
disease burden both physically and economically as it affects the female population. The 
literature is consistent in identification of modifiable risk factors that account for >80-90% 
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of the disease burden. The appraised literature is replete with the recommendation and 
significance of cardiovascular risk screening in asymptomatic adults as well as the 
deficiency in screening currently observed in the clinical practice setting. Risk 
assessment algorithms may be used to identify modifiable risk factors, raise awareness 
of CVD, educate, prompt risk modification, and predict both short and long term risk of 
developing CVD.   
 The goal of early CVD risk identification in asymptomatic adults is to provide 
targeted interventions to reduce or eliminate the risk and change the trajectory of CVD 
progression. Summarization of the current evidence, as reported in the literature by 
experts in the field of cardiovascular disease, deduced that many risk prediction models 
are reliable and valid but that all models have limitations. All of the validated models 
assess for a core number of modifiable risk factors including blood pressure, smoking 
status, blood glucose, lipid analysis, physical activity, and BMI. Many of the models, 
especially the European models, assess for additional risk factors such as depression, 
anxiety, socio-economic factors as well as additional biologic markers such as CRP-hs 
and additional lipoprotein analysis.  
 The goal in CVD prevention is to produce the largest relative risk reduction, the 
smallest number needed to treat, and the lowest cost per quality-adjusted life year saved 
(Ashen, 2010). To be clinically relevant, a risk prediction model must be robust and must 
be clinically applicable considering the patient population, practice setting, time 
constraints, cost, and objective for implementing a CVD risk prediction model in the 
clinical setting. In clinical practice, risk prediction algorithms have been used most 
directly to identify individuals at risk for developing CVD and institute interventions to 
reduce morbidity and mortality of the disease. The 16 high level of evidence summaries 
all substantiated the use of the FRS model as a universally accepted risk prediction 
model in the U.S. and recommended its use as a primary prevention measure. This DNP 
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project manager employed the FRS model to the identified study population with 
resultant findings to be discussed in-depth in chapter three.    
Construction of the EBP project 
 Intertwining Pender’s health promotion model and Stetler’s evidence-based 
model with rigorous integration of current evidence provides a cogent foundation for this 
evidence-based practice project. The detailed implementation process will be discussed 
throughout the project paper. 
Best practice recommendation 
Risk scores can be useful educational and motivational tools for patients. The 
best practice model is one that is implemented by practicing clinicians and employs 
primary prevention performance guidelines for assessment of CVD risk in the 
asymptomatic patient utilizing a multivariate risk model. This DNP project manager has 
the knowledge and clinical expertise to implement the risk assessment screening tool in 
the identified practice setting. The best practice recommendation is one that is valid and 
reliable and is applicable to the constructs of the PICOT question. The Framingham risk 
score (FRS) model was chosen for this EBP project for its ability to consistently predict 
risk assessment in asymptomatic women.   
Answering the clinical question   
The best practice recommendation answered the clinical question: In women 
ages 35-50 presenting for their annual gynecologic exam and are asymptomatic for 
CVD, how does implementation of the FRS compared to usual care (no screening), 
identify the level of CVD risk over a three month period of time? The DNP project 
manager negotiated with the practice manager and CEO regarding the implementation 
process and the need for provider and staff buy-in. The DNP project manager initiated 
strategies with the staff regarding the significance of gleaning CVD risk prediction data. 
In concordance with the Lifestages mission statement which includes advocating for, 
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development of, and implementation of quality, comprehensive, and cost effective health 
care programs which educate, inform and support women in making their health care 
choices and in living healthful lives was repeatedly reiterated to the identified 
stakeholders. The DNP project manager reinforced the vision of the practice which is to 
provide comprehensive health care across the lifespan with uniform excellence in quality 
and service. The DNP project manager educated the clinical staff on the scope of the 
problem, procuring the informed consent, on garnering the required metrics, and on the 
process of appropriating the completed data to the DNP project manager. The DNP 
project manager inputted data into the web based FRS prediction tool and elicited risk 
stratification for each person in the EBP project. Statistical data analysis was computed 
using the SPSS 20 statistical analysis program.  
  Inclusion of the clinical staff in study purpose and significance, data gathering 
and education promotes team work and a sense of accomplishment. Staff realization 
that they were being influential in the potential improvement in health outcomes of the 
patients they serve provided a sense of worth and a feeling of making a difference 
versus only performing a job.  
 Dissemination of study results were shared with the clinical staff as well as with 
individual patients on follow up appointment. Enhanced collegiality among the provider 
staff was procured through diffusion of the EBP project findings. Further dissemination of 
clinically relevant data was accomplished through scholarly publication, community 
educational presentations, and through local and national professional organizations.  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
 Evidence based practice is the salient commitment to the implementation of 
theory-derived and research-based evidence in making critical thinking decisions 
regarding provision of health care. It is not enough to have knowledge of the best 
evidence to guide clinical practice; that knowledge must be translated into clinical 
practice to improve patient care and outcomes (Hockenberry, Brown, & Melnyk, 2011). 
The method used for the design and implementation of the EBP project will be discussed 
in detail in this chapter. Amalgamation and management of data as well as protection of 
human subjects will also be discussed. 
Sample/Setting 
 The EBP project participants originated from a convenience sample of women 
who met inclusion criteria and provided informed consent to participate. In a 
convenience sample the inclusion criteria is identified prior to selection of project 
participants and all persons who meet the inclusion criteria are welcomed to participate 
(White, 2012). Because the sample is selected for ease of data collection, this sample 
may not be representative of the target population. This may well be the case in the 
instance of this EBP project as the office setting chosen, again due to ease of project 
implementation, is only one of five office settings for this OB/GYN practice. The 
probability for bias is high in a convenience sample as again it may not be representative 
of the target population. Strategies to control for bias were utilized such as comparing 
demographic data from individuals in the EBP project to general population 
demographics to determine if the project sample is representative of the general 
population. 
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 Lifestage’s Centers for Women has five practice settings located in southern 
Ohio. The provider staff of Lifestage’s consists of eight OB/GYN physicians, four certified 
nurse midwives (CNM), and one board certified family nurse practitioner (FNP). On any 
given work day, there can be anywhere from two to four medical providers working in the 
EBP project implementation clinical practice site. Lifestage’s offices are diverse in both 
their location and the populations they serve. Of the five practice sites, one is located in 
an affluent upper class area of the region, two are located in inner city lower income 
areas, another in a low to middle class environment and the fifth practice setting is 
located in a middle to upper class area of the city.   
 The practice setting that was utilized for this EBP project is located in an upper 
middle class neighborhood which is easily accessible via a major highway, has ease of 
parking, and is also adjacent to a city bus route. The clinical practice site is located 
within a large multi-faceted outpatient facility. Many patients take advantage of this 
location for its accessibility and functionality. Because of the myriad of services available 
in this outpatient facility, many patients take advantage of this setting because they can 
consolidate other testing such as mammography and laboratory testing in conjunction 
with their medical appointment. This location is an encashment area for several smaller 
communities that surround the facility therefore providing a wide diversity of population 
demographics. Among the smaller communities that predominantly employ this 
outpatient setting are small farming communities, a large German Baptist community, 
and small communities that extend toward the Richmond Indiana area.  
 Design 
 The purpose of the EBP project was to implement cardiovascular disease risk 
assessment screening using the Framingham Risk Score (FRS) model in asymptomatic 
women to identify and stratify their level of CVD risk. The EBP project is designed as a 
primary prevention intervention. The tacit goal of primary prevention is the attempt to 
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prevent disease from occurring. Primary prevention therefore reduces both the incidence 
and prevalence of a disease. CVD is particularly suited for application of primary 
prevention because it is common, occurs at a high incidence, can be modified by 
behavior, has a long latency period, incurs high financial costs, and has a high societal 
burden (Ashen, 2010). The health care arena has traditionally focused on secondary and 
tertiary levels of prevention, the foci being on treating disease once it has occurred 
rather than preventing it from occurring. Compelling evidence exists garnering the 
importance of primary disease prevention as it relates to CVD in women. Cardiovascular 
disease risk assessment and stratification can theoretically raise population and 
individual awareness of disease and motivate changes in behavior to improve health and 
health outcomes as well as decrease the economic burden of CVD.  
Strategies for education and dissemination of information regarding the EBP 
project included PowerPoint presentations, e-mail communication, role playing, and a 
scripted module for the medical assistant to employ while explaining the EBP project to a 
potential project participant. The DNP project manager developed two PowerPoint 
presentations, one that was specific to the provider staff and practice administrators and 
one specific for the medical assistant and R.N. staff. The PowerPoint presentations were 
presented to and approved by the CEO and the office practice manager prior to 
dissemination to the staff.   
The PowerPoint presentation for the medical provider staff was presented at the 
monthly provider meeting and included CVD background and significance, evidence and 
research related to CVD risk prediction, practice mission and vision statements, EBP 
project objectives, and implementation process. Time was allotted for feedback, critique 
and questions regarding the project and its implementation.  
The PowerPoint presentation was presented to the office staff, including MA’s, 
RN’s, practice manager and office manager, at their monthly meeting which included 
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CVD significance and background as well as an outlined step by step methodology for 
the MA role in the project implementation. A script was prepared for the MA’s which 
presented a dialogue to incorporate into the patient interview process, therefore 
providing a consistent procedural methodology in which to communicate and interact 
with potential EBP project participants. Role playing was incorporated into the 
presentation agenda in which the MA’s simulated an interaction with a potential project 
participant. The role playing module addressed various scenarios and potential 
questions that an EBP project participant may have. During the role playing activity, 
brain storming and suggestions were made by those observing the role play interaction. 
Additional presentations were scheduled over lunch hours and before and after office 
hours to capture those absent from the aforementioned meetings.  
A bulleted laminated step by step protocol was provided to the MA’s and was 
also made available in the work station and provider offices, to quickly ascertain 
inclusion criteria and applicability for participation in the EBP project. The DNP project 
manager sent frequent email reminders regarding the EBP project and encouragement 
to be participative in recruiting applicable project participants. Access to the DNP 
manager included in-basket computer communication as well as phone communication. 
When the DNP project manager was working at the implementation site, she was 
available for face-to-face questions or concerns and would make contact with the 
medical assistant several times throughout the work day.  
The DNP project manager identified inclusion criteria for potential EBP project 
participants to include a convenience sample of women between the ages of 35-50 who 
did not have a diagnosis of cardiovascular disease, in other words, were not being 
treated for dyslipidemia, hypertension, or type II diabetes. The sample consisted of 
women who presented to the Samaritan North office of Lifestage’s Centers for Women 
for their annual preventive gynecologic exam.  
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The screening process was delineated in a step by step process for the medical 
assistant staff as well as the provider staff. When the MA arrived for the day, she printed 
out the schedule of the provider that she would be working with that day. The MA then 
looked at the ages of the patients and identified those who fell into the 35-50 year old 
age range. She then looked at the visit type and identified those women who were 
scheduled for their annual preventive exam versus an acute problem or a pre-op patient. 
The MA then notated next to the patient name, with an asterisk, that this patient met 
initial inclusion criteria. Before the patient arrived, the MA checked the patient chart for 
diagnosis of hypertension, dyslipidemia, or type II diabetes that would exclude them from 
participating in the EBP project. If the patient met all of the inclusion criteria the MA 
offered CVD risk screening to the patient during the interview process using the scripted 
dialogue that was presented during the role playing portion of the staff meeting. Using a 
standardized script, the MA explained briefly the significance of CVD in women, goals 
and objectives of the EBP project and if the patient consented, what the process would 
entail for the patient. If the patient desired to participate, the MA obtained a signed 
informed consent form. The informed consent form contained the elements of the title of 
the project, aim/purpose of the project, the DNP project manager information, risk/benefit 
to the patient, assurance that all patient information would be held in strict confidentiality, 
and that participation in the EBP project was voluntary and without monetary 
compensation. It was also articulated to the patient that she would be responsible for 
any laboratory co-pays or fees. Ascertainment of understanding was elucidated and any 
questions were answered, after which the patient signed the consent form. Once the 
patient signed the informed consent form, the MA apprized the medical practitioner of 
the patients’ consent to participate in the EBP project. During the patient exam, the 
medical practitioner reinforced the significance of CVD risk assessment in women and 
the objective of the EBP project, answered any questions that they may have had, and 
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ordered the fasting laboratory testing consisting of a comprehensive metabolic panel 
(CMP) and a lipid panel. The laboratory testing was ordered for the patients’ laboratory 
of choice or laboratory that was deemed appropriate by the insurance carrier. The MA 
completed the data entry form and attached it to the consent form and placed them in a 
folder in the nurses work station for the DNP project manager to collect (Appendix A&B). 
The DNP project manager collected the forms on a daily basis and procured them in a 
secure location to maintain patient privacy and confidentiality.  
The DNP project manager frequently queried lab results for patients who had 
consented to project participation. Once the laboratory testing was complete, the DNP 
project manager entered the data into the FRS model database and obtained risk score 
results which were printed out in duplicate. One set of the results were scanned into the 
electronic medical record (EMR) and the other was maintained by the DNP project 
manager to input into the SPSS-20 statistical program.   
 Once the data had been collected and inputted into the FRS model and risk 
identification has been gleaned, the DNP project manager made the determination 
whether or not the patient required a follow up appointment. Those individuals who had 
identified CVD risk were notified by the R.N. to make a follow up appointment with the 
FNP, the patient’s primary care provider, or for cardiology referral to review the FRS 
results and adjudicate a plan of care. 
 In tandem with the clinical practice marketing director a thank you letter was 
drafted and approval by the CEO and practice manager which was then mailed out to 
each EBP project participant. The letter thanked the participant for being proactive in her 
CVD health and included a red dress pin, a hallmark identifier for CVD awareness, as 
well as a print out of her FRS model data with interpretation. A total of three letters were 
drafted, one for normal risk factors, another for abnormal risk factors requiring a follow 
up appointment, and a third letter informing the patient that the laboratory testing was 
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normal but that BMI is elevated and offering suggestions that may assist the patient in 
reducing BMI (Appendix C, D, & E).  
The marketing director interviewed the EBP project manager for an article in the 
quarterly Lifestage’s newsletter that is available on the practice web site, available in the 
office, as well as a direct mass mailing to the community. The marketing director is also 
responsible for setting up health talks within the community and has involved the DNP 
project manager as a speaker on CVD as it relates to women in a variety of community 
venues.  
A strong commitment exists within the practice and with the medical practitioners 
to have ongoing assessment of CVD risk in women. The outcome data from the EBP 
project provided compulsory evidence supporting the need to screen asymptomatic 
women for CVD risk and rendered credence to the need for a permanent clinical practice 
change. It is imperative to continue to provide credible data, education on the 
significance of CVD risk as it pertains to the female population, and emerging trends in 
CVD risk prevention to improve the health of women.  
Instrument 
  Accurate and timely risk estimation and identification of individuals at increased 
risk for CVD is the cornerstone of CVD prevention. Clearly, risk prediction models must 
be based on statistically sound methods and should accurately estimate risk in the 
sample population. The ability to accurately assign individuals to categories of risk where 
the observed rate of disease correlates to the risk prediction is evidence of a valid risk 
prediction model. Clinical risk profiling is recommended by clinical practice guidelines as 
a foundational beginning for the evaluation of asymptomatic individuals in identification 
of CVD risk level.  
 The Framingham risk assessment model was the instrument utilized to 
prognosticate CVD risk in this EBP project. The concept of risk factors for CVD 
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identification, introduced by the Framingham Heart Study, serves as the gold standard 
for CVD risk assessment. The Framingham risk score is a multivariable mathematical 
risk equation that predicts a 10-year risk of developing CVD events. In addition to 
determination of 10 year risk levels, the FRS model also delineates vascular heart health 
age based on risk factor stratification as it compares to chronological age. For example, 
based on risk factors, a 59 year old female may have the heart health age of a 48 year 
old or vice versa. This delineation may provide a greater significance and understanding 
for the individual patient versus a 10 year risk percentage number.  
 The Framingham Heart Study remains the most famous and influential 
investigation in CVD epidemiology, and since its inception in 1947, has garnered over 
2000 peer reviewed articles (Oppenheimer, 2010). The Framingham Study has provided 
insights into the prevalence, incidence, prognosis, predisposing factors, and 
determinants of CVD. The scientists involved with the Framingham Heart Study were 
instrumental in changing the concept of chronic disease into discernment of probability 
and disease prevention. Through population based randomized controlled trials and 
observational cohort studies in diverse population samples, the researchers associated 
with the Framingham Heart Study were able to effect change in how clinicians 
approached CVD as well as the efficacious applicability of primary prevention.   
 The metrics assessing the parameters of a risk prediction model must evaluate 
its ability to discriminate future cases from non-cases, determine the ability of the model 
to inform regarding the outcome of interest, and the calibration of the model related to its 
validity and reliability (Llyod-Jones, 2010). The most widely reported measure of model 
discrimination for CVD risk prediction models is the C statistic. The C statistic is a 
function of both the sensitivity and specificity of the model across all of its values, and it 
represents the ability of the score to discriminate cases from non-cases (Llyod-Jones, 
2010). In simplistic terms, the C statistic indicates the probability that a randomly 
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selected individual who develops disease would have a higher risk score than a 
randomly selected individual without disease. The C statistic can vary from 1.0, which is 
perfect discrimination, to 0.5 which is equivalent to random chance. C statistics between 
0.70 and 0.80 are considered to be acceptable and those that fall between 0.80 and 0.90 
are considered to be excellent (Lloyd-Jones, 2010). A combination of multiple 
independent risk markers, as in the Framingham risk score model, provides magnitude 
of relative risk and C statistics that typically range from 0.75 to 0.80. The Framingham 
risk score model discriminates risk better for women than men with C statistics that are 
generally >0.80 for women (Lloyd-Jones, 2010). Measures of calibration assess the 
ability of a risk prediction model to predict accurately the absolute level of risk that is 
subsequently observed. For example, if a risk prediction model is well calibrated an 
observed event rate would be similar to the level of risk identified by the model, so if an 
individual has a 7% risk of a CVD event over 10 years, the observed event rate should 
also be close to 7%. Other measures such as likelihood ratio tests and the Bayes 
information criterion are commonly used to assess the utility of risk prediction models. 
These tests when statistically significant can indicate whether a risk model is predicting 
disease incidence better than by chance alone (Lloyd-Jones, 2010).  
 The literature review has been succinct in identification of significance and 
variance of risk factors as they pertain to gender differences in CVD risk. Although the 
classic risk factors are the same for women and men, there are gender differences in the 
prevalence and significance of the various risk factors. The clustering and 
interrelationship of multivariate risk factors exhibit different risk levels based on gender. 
The Framingham risk score model has a gender specific score model which enhanced 
its applicability in the identified EBP project population.  
 
 
SCREENING CARDIOVASCULAR RISK  61 
 
Measurement 
 The Framingham Heart Study generated seminal findings such as the effects of 
tobacco use, unhealthy diet, physical inactivity, obesity, hypertension, dyslipidemia, and 
diabetes on the development and progression of CVD (Mendis, 2010). The Framingham 
Risk score model, using a sex specific multivariate risk factor algorithm, was used to 
assess CVD risk for each individual EBP project participant. Electronic calculator web 
based data analysis was completed on each EBP project participant. The data was 
inputted into both of the gender specific FRS models, which included the laboratory data 
base and the body mass index (BMI) data base (Appendix F & G).The FRS spreadsheet 
provides a rapid visualization of the gleaned data including percentage of risk over a 10 
year period of time as well as each individuals estimated vascular or heart age. Each 
data spreadsheet was printed and scanned into the patient EMR where is can easily be 
accessed by the patient’s team of medical providers.  
Outcomes 
 Data analysis is “the process of breaking down, examining, comparing, 
conceptualizing, and categorizing data” (Mauk, 2012). Once the intervention has been 
implemented it will be imperative to evaluate the effectiveness of the intervention. 
Rigorous analysis of the project outcomes must be corroborated with the EBP project 
goals and objectives as well as the PICOT question. Questions must be propagated 
regarding outcome achievement and analysis of all possible factors that may have 
impeded the desired outcome if the EBP project objectives were not met. Initiatory 
outcomes demonstrated a significant percentage of women who had identified CVD risk 
factors and required additional follow up.  A meticulous analysis of the data will be 
articulated in detail in Chapter four. 
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Implementation of practice change 
 It is imperative to be cognizant of and anticipate potential barriers to changing 
clinical practice, among these conceivable barriers are organizational culture, belief 
systems, and research related barriers (Young, 2012). The word change evokes a 
myriad of defining characteristics which can be quite disparate from one individual to 
another. Some individuals view change as positive and challenging where others may 
view change as negative and a divergence from the status quo. Identifying strategies to 
implement change in a positive manner will be the catalyst to making a smooth transition 
to a new clinical practice paradigm. Applying a simplistic change model such as Kotter’s 
eight change phase’s model in conjunction with the Stetler model of EBP will promote a 
venue for a positive change transition. The eight change phases include creating a 
sense of urgency; creating a guiding coalition; developing a change vision; 
communicating the vision; empowering broad-based action; generating short-term wins; 
don’t let up; and make it stick (Kotter,1996).To lead change successfully Kotter and 
Schlesinger (2008) recommend analyzing situational factors, determining the optimal 
speed of change, develop methods to manage resistance, educate, communicate, 
encourage participation, negotiate, facilitate and support. The reader may refer back to 
chapter two for in depth detailing of the foundational models.  
 When evaluating the outcomes of an EBP implementation, it is important to 
realize that EBP fosters common goals such as improved patient care and best practice 
through interdisciplinary collaboration (Fineout-Overholt, Melnyk, & Schultz, 2005).  
Providing EBP project outcome data to the practitioners and staff in the clinical setting 
will garner collegiality and support among the entire staff and modulate a clinical practice 
change. The goal of implementation of the EBP project is to generate outcomes that will 
support the need for a best practice clinical practice change. By sharing knowledge, 
evidence, research, and outcomes, EBP guidelines can influence consistency and best 
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practice in the clinical practice setting. Demonstration of significance will support the 
need to make CVD risk prediction screening a clinical practice change to both align with 
the mission and vision of the practice as well as a commitment to improve the health of 
the women we care for.  
 Not only does an EBP clinical practice change affect the clinician’s practice 
behavior but it also unequivocally affects the patient. Dissemination of risk findings must 
be communicated in a manner that will make an impact with the patient. Evidence-based 
practice is based on the three components of research-based knowledge, clinical 
expertise, and patient preference and needs. Patient preference is perhaps the most 
challenging component of the EBP process. As a clinician, developing a partnership with 
the patient is prima facie to the success of sharing information and being instrumental in 
partnering with the patient to mitigate positive health behavior changes.  
 Applying Pender’s Health Promotion Model as a foundation for the EBP project 
facilitates identification of the motivation in individuals that will promote a behavioral 
change as well as potential barriers that inhibit adapting positive health practices. When 
Pender’s HPM is implemented in clinical practice, it can be an efficacious tool in 
increasing patient awareness of their risk factors and facilitating movement toward 
positive health practices and improved health outcomes. As previously elucidated, the 
FRS model will determine 10 year risk of developing a cardiovascular event but will also 
report a person’s heart age based on obtained metrics. This knowledge may be more 
tangible and motivating for an individual to make healthy lifestyle changes than a 10 year 
risk percentage number that may be difficult for the patient to conceptualize. Aggressive 
primary prevention in asymptomatic women is crucial in reversing the ominous trend of 
CVD morbidity and mortality.  
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Management of data 
 Continuous variable dichotomization is a popular technique used in estimation of 
the effect of risk factors on health outcomes in multivariate regression settings. The 
validity and reliability related to the prognostication of the FRS model has previously 
been discussed. Measurement of the impact of the EBP project primary prevention 
intervention was analyzed by descriptive and inferential statistics using the SPSS 20 
statistical program. Descriptive statistics and frequencies were used to describe the 
demographic data of the project sample. Correlational relationships between variables 
further delineated significance of modifiable risk factors. One of the initial identified 
deterrents to completing the screening was the need for laboratory testing to be done 
with the patient fasting. The FRS model has two gender specific databases, both which 
are inclusive of age, smoking status, and blood pressure. In addition to the above 
mentioned variables, one database uses laboratory testing and the other uses BMI 
instead of laboratory testing. This BMI version of the FRS model may be easily 
implemented in the clinical practice setting where there may be logistical constraints 
such as lack of readily available laboratory settings or where compliance may be an 
issue. Further discussion related to EBP project implementation weaknesses and 
strengths will be considered in Chapter five.  
Protection of human rights  
 Institutional review board approval was received by Valparaiso University and 
approval for the EBP project was obtained from the clinical practice site administration 
prior to implementation of the EBP project. Expedited review was obtained based on 
minimal risk to the patient and significant potential for positive benefit gleaned from the 
EBP project.  
 Strict confidentiality was maintained throughout the EBP project. Personal data 
and demographics were maintained in a secure locked file in the practice setting and 
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once data was inputted into the FRS model data base, the identifying data was 
shredded.  
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CHAPTER 4 
FINDINGS 
The purpose of the EBP project was to screen asymptomatic women between 
the ages of 35-50 to identify modifiable CVD risk factors as well as their level of CVD 
risk. This EBP project was implemented in the clinical practice setting of a large 
women’s health practice in Southern Ohio. The clinical question in PICOT format was: In 
women between the ages of 35-50 presenting for their annual gynecologic preventive 
exam, who are asymptomatic for CVD, how does implementation of the Framingham 
Risk Score (FRS) model, compared to usual care (no screening), identify the level of 
CVD risk over a 3 month period of time? The intended outcome of this primary 
prevention EBP project was to identify and stratify CVD risk factors in asymptomatic 
women, in other words women who are not being treated for hypertension, dyslipidemia 
or type II diabetes. Identification of CVD risk in asymptomatic women allows for early 
intervention to reverse risk factors and change the trajectory of CVD development. The 
outcomes and data analysis of this primary prevention EBP project, which addresses the 
clinical question, will be promulgated in this chapter.  
Demographic data was collected on 148 participants who agreed to participate in 
the EBP project and signed the consent form. The descriptive demographic metrics that 
were gleaned included age, race, marital status, employment status, insurance status, 
smoking status, and family history of CVD in a first degree relative at or before the age 
of 55. These variables were obtained by the medical assistant (MA) at the time of the 
patient appointment and were recorded on the patient data form.  
Sample characteristics 
 All of the EBP project participants were female (n=148) between the ages of 35-
50. The mean age was 42.93 (SD = 4.73). Age distribution is visually depicted below in 
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Figure 4.1. Age frequencies were fairly well distributed across the age range with the 
exception of age 39 which consisted of only two participants.  
Figure 4.1 Age Distribution n=148 
 
Of the 148 women who signed consent forms to participate in the EBP project, 
109 completed the laboratory testing, accounting for 73.6% of the original cohort. Table 
4.1 visually depicts the characteristics of the sample who completed the laboratory 
testing (n=109). Ethnic demography was comprised of 79.8% Caucasian, 18.3% African 
American, and 1.8% Asian women. Among marital status 66.1% were married, 10.1% 
divorced, and 23.9% were single. Of those who identified themselves as single, it was 
not ascertained if they were single never married or defined themselves as single due to 
divorce. The majority of the women were employed, 85.3% while 14.7% were 
unemployed. The status of employment was undeterminable in regard to employment 
status being full time, part-time, or prn status. Insurance status included 80.7% of study 
participants who had commercial insurance, such as United Healthcare, Aetna, or 
Anthem, 14.7% were on Medicaid and 4.6% were uninsured. None of the study 
participants were on Medicare insurance.  
SCREENING CARDIOVASCULAR RISK  68 
 
In the sample completing the laboratory testing, 14.7% were smokers, 75.2% 
were non-smokers, and 10.1% were former smokers. Unfortunately there is neither data 
available regarding the amount of cigarettes smoked per day or the duration of smoking 
history. 
  There is strong epidemiologic evidence for the familial aggregation of CVD and 
the researchers from the Framingham Heart Study reported that having CVD in at least 
one first degree relative increased the risk of CVD in women by 70% (Imes & Lewis, 
2013). A positive family history of CVD in a first degree relative prior to the age of 55 
included 36.7% of women while 63.3% of the project participants did not have family 
history of early CVD. This subjective data may be biased as some participants may be 
unclear as to what defines CVD and may not be fully apprised of the extent of their 
family history.  
 A comparison of demographic characteristics was effectuated with those who did 
not complete the laboratory testing (n=39) and these results are depicted in Table 4.2. 
The demographic comparison was generated to determine if those who did not complete 
the laboratory testing were similar in characteristics to the cohort sample that did 
complete testing. Of the n=39 who did not complete testing, 82.1% were Caucasian, 
15.4% African American and 2.6% Asian. The majority were married, 66.7% with 10.3% 
divorced and 23.1% single. 76.9% of this sample were employed with 23.1% being 
unemployed. The majority of these women had commercial insurance, 79.5% while 
15.4% had Medicaid and 5.1% were uninsured. None of this cohort of women had 
Medicare insurance. Non-smokers constituted 82.1% of this group, 15.4% were 
smokers, and 2.6% identified themselves as former smokers. A positive family history of 
CVD in a first degree relative at or before the age of 55 was depicted in 28.2% of this 
population while 71.8% did not have this history.  
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 The demographics of the cohort sample that followed through with the CVD 
screening were similar to those who did not complete the testing. These similarities are 
germane in providing strength to the generalizability of the EBP project findings to the 
general population. One comparison of interest to note was that more women who 
completed the testing were employed (85.3%) compared to those women who didn’t 
complete the testing (76.9% employed) demonstrating the largest variance in 
demographic data.  
Table 4.1 
Sample characteristics of women completing the laboratory testing n=109  
Trait________________________________________________Frequency (n) results_________ 
Gender        100% female (n=109) 
Ethnicity       79.8% Caucasian (n=87) 
        18.4% African American (n=20) 
        1.8% Asian (n=2) 
Marital Status       66.1% married (n=72) 
        10.1% divorced (n=11) 
        23.8% single (n=26) 
Employment Status      85.3% employed (n=93) 
        14.7% unemployed (n=16) 
Insurance       80.7% commercial (n=88) 
        14.7% Medicaid (n=16) 
        4.6% uninsured (n=5) 
Family History of CVD before age 55    36.7% yes (n=40) 
        63.3% no (n=69) 
Smoking Status       14.7% smoker (n=16) 
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        75.2% non-smoker (n=82) 
        10.1% former smoker (n=11) 
         
Table 4.2 
Sample characteristics of the women not completing laboratory testing n=39 
Trait        Frequency (n) results  
Gender        100% female (n=39) 
Ethnicity       Caucasian 82.0% (n=32) 
        African American 15.4% (n=6) 
        Asian 2.6% (n=1) 
Marital status       Married 66.7% (n=26) 
        Divorced 10.3% (n=4) 
        Single 23.0% (n=9) 
Employment status      Employed 76.9% (n=30) 
        Unemployed 23.1% (n=9) 
Insurance status      Commercial 79.5% (n=31) 
        Medicaid 15.4% (n=6) 
        Uninsured 5.1% (n=2) 
Family history of CVD before age 55    Yes 28.2% (n=11) 
        No 71.8% (n=28) 
Smoking status       Smoker 15.4% (n=6) 
         Former smoker 2.6% (n=1) 
        Non-smoker 82.0% (n=32) 
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Changes in outcomes: statistical testing and significance 
 The interval variables assessed included systolic blood pressure (SBP), diastolic 
blood pressure (DBP), total cholesterol (TC), triglycerides (TG), LDL cholesterol, HDL 
cholesterol, blood sugar, and BMI. These variables with their frequencies are delineated 
in Table 4.3. Although the aforementioned variables were assessed and are considered 
individually and collectively as CVD risk factors, only systolic blood pressure (SBP), total 
cholesterol (TC), HDL cholesterol, blood sugar, smoking and age are considered in the 
laboratory FRS prediction model. Age, smoking, SBP, and BMI are considered in the 
BMI arm of the FRS model. The FRS models are gender specific. The measures of 
central tendency will be articulated in the following section.   
Systolic blood pressure is considered normal if ≤140 mg/Hg. The spectrum of 
systolic blood pressure readings ranged from 98 to 152 with a mean of 121.68 
(SD=11.32). Of the 109 EBP project participants 6% exhibited systolic blood pressure 
readings above the normal. Normal diastolic blood pressure is considered to be ≤90 
mm/Hg. The array of readings ranged from 60 to 110 with a mean of 77.76 (SD=8.16) 
with a resultant 16% of the EBP project participants having reading ≥90.  
Normal total cholesterol level recommendation is ≤200. The range notated in the 
study was 121-281 with a mean total cholesterol of 188.44 (SD=33.42). Of the 109 
project participants, 38% had total cholesterol scores of ≥200. Triglycerides (TG) 
guidelines recommend the level to be ≤150. The readings of TG’s ranged from 32-373 
with a mean of 103.56 (SD=64.16). 20% of the project participants had TG levels that 
were ≥150. HDL cholesterol is the cholesterol that exerts a cardio-protective effect if the 
levels are ≥40. The range in the EBP project participants ranged from a low of 36 to a 
high of 118 with a mean of 59.42 (SD=16.24). Of the 109 project participants 12% 
exhibited levels of HDL that were ≤40. LDL cholesterol plays a major role in the 
development and progression of CVD. The accepted range for LDL cholesterol is ≤100 
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unless a patient has co-morbidities such as hypertension or type II diabetes, which then 
LDL cholesterol is recommended to be less than 70. The range in the EBP study 
population was 40-204 with a mean of 108.46 (SD=32.03). Data analysis demonstrated 
58% of the project participants garnering LDL levels ≥100. Normal fasting blood sugar 
should be ≤100, the EBP project range for blood sugar was 77-169 with a mean of 92.34 
(SD=12.46). 20% of the participants demonstrated a blood sugar that was ≥100.  
A normal BMI is considered to be ≤24.9, overweight 25-29.9, obese 30-34.9 and 
morbid obesity ≥35. The range observed with the EBP project participants ranged from 
19.69-54.03 with a mean of 30.06 (SD=7.00). 23.9% of the study population had a 
normal BMI of ≤24.9; 30% of the cohort had BMI’s that fell between 25-29.9; 22.2% had 
BMI’s between 30-34.9; and 23.9% demonstrated a BMI of > 35.  
 Prognostication of CV risk has historically been disparate among leaders in CV 
health and risk assessment. The most current recommendation as acceded to by the 
American College of Cardiology, the American Heart Association, and the researchers 
from the Framingham Heart Study categorizes women as being at ideal CV risk, at risk, 
or being at high risk for the development of CVD. The most current FRS model scores 
delineate percentage of risk estimation as low risk (< 6%), moderate risk (≥ 6% and < 
10%), moderate-high risk (≥ 10 and < 20%), and high risk (≥20%) (Tattersall, Gangnon, 
Karmali, & Keevil, 2012). These percentages estimate the risk of developing a CV event 
over the course of the next ten years.   
FRS percentages ranged from 0.8% to 15.7% with a mean of 3.2991 (SD=2.53). 
Utilizing the percentages delineated above, 100 of the EBP project participants or 92% 
were identified as being at low risk, 5 (5%) were considered to be at moderate risk, and 
3 (3%) were identified as being at moderate/high risk.  
In addition to delineating a risk percentage score for development of a CV event 
over the duration of a ten year period of time, the FRS also reports a vascular heart age. 
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The vascular heart age compares one’s chronologic age to the age of the heart muscle 
taking into consideration various identified risk factors. For example, a 40 year old 
woman with multiple CVD risk factors may have a heart age that is equivalent to that of a 
65 year old woman without risk factors. The FRS informing of the vascular heart age 
compared to the person’s chronologic age provides a tacit mechanism in which to 
convey the significance of CVD risk factors to the patient as they relate to the health of 
the heart muscle.  
Using the laboratory metrics (TC, HDL cholesterol and blood sugar) and gleaned 
assessment data (age, smoking, and SBP), the variables were inputted into the FRS 
model and heart age was determined. Of the n=109 who completed the laboratory 
testing 42% (n=45) had a heart age that exceeded their chronologic age; 1% (n=2) had a 
vascular heart age that was equivalent to chronologic age; and 57% (n=62) had a 
vascular heart age that was less than their chronologic age. Using BMI instead of 
laboratory testing, the variables of age, smoking, SBP, and BMI were entered into the 
FRS prediction tool. Of the n=109 EBP project participants, 58% (n=63) had a vascular 
age that was greater than their chronologic age; 8% (n=9) had a vascular heart age 
equivalent to their chronologic age; and 34% (n=37) had a vascular heart age that was 
less than their chronologic age. 
If basing clinical decisions on risk level alone, many women would not receive 
primary prevention intervention education and strategies to reduce identified modifiable 
risk factors. As will be elucidated in the following section, the majority of women did 
exhibit modifiable CVD risk factors which were identified through the risk assessment 
screening.   
 Systolic blood pressure, diastolic blood pressure, BMI, smoking, TC, TG, LDL 
cholesterol, HDL cholesterol, and blood sugar were the nine modifiable risk factors that 
were assessed with the EBP project. Graph 4.2 visually depicts the identified risk factors 
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along with the frequency distribution. Graph 4.3 visually correlates each study participant 
(n=109) with the number of modifiable risk factors each participant possessed. Only 9% 
of the project participants didn’t have identified risk factors and would be considered to 
be at ideal CV health as defined by the AHA. 13% had only one identified risk factor; 
27% had two identified risk factors; 16% had three identified factors; 16% had four risk 
factors; 9% had five risk factors; 7% had six risk factors; 2% had seven risk factors and 
only one person (1%) had eight identified risk factors. The significance of the identified 
CVD risk factors will be discussed in detail in chapter 5.  
Figure 4.2 
Modifiable variables and their frequencies  
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Figure 4.3  
Number of modifiable risk factors and their frequency within the study population n=109 
 
 Correlation is a statistical technique that is used to measure and describe the 
degree and direction of the linear relationship between two variables (Gravetter & 
Wallnau, 2008). In the data analysis that was performed using Pearson’s Correlation 
Coefficient (Pearson r) it can be determined if there is a direct correlation between two or 
more specific variables. Correlations can be used for a number of applications including 
prediction, validity, reliability, and theory verification (Gravetter & Wallnau, 2008). The 
correlation coefficient will be between -1.0 and +1.0. Correlations that are above +0.7 or 
below -0.7 represent a strong correlation between the tested variables (Cronk, 2010). A 
positive correlation indicates that as one variable gets larger, the other variable will also 
get larger. Conversely, a negative correlation indicates that as one variable gets larger 
the other variable will get smaller (Cronk, 2010). Correlations are reported numerically 
as the correlation, the significance, and the n, with degrees of freedom being n -2 
(Cronk, 2010). The significant correlations that were gleaned will be delineated below. 
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Table 4.3 Correlation Table 
______________________________________________________________________________ 
     Variable Correlation      Result              Significance ___ 
SBP/DBP 
 
 
 
 
 
 
Age/FRS 
 
 
 
 
 
SBP/FRS 
 
 
 
 
 
Age/BMI heart age 
 
 
 
 
 
 
SBP/BMI  
 
 
 
 
 
LDL/TC 
 
 
 
 
 
 
LDL/HDL 
 
 
r (107) = 0.735, p <0.000 
 
 
 
 
 
 
r (107) = 0.446, p <0.000 
 
 
 
 
 
r (107) = 0.516, p < 0.000 
 
 
 
 
 
r (107) = 0.539, p <0.000 
 
 
 
 
 
 
r (107) = 0.340, p < 0.000 
 
 
 
 
 
r (107) =0.892, p < 0.000 
 
 
 
 
 
 
r (107) = -0.307, p < 0.001 
 
 
Represents a strong positive 
correlation indicating that a 
significant positive linear 
relationship between the two 
variables exist; indicating that 
as SBP increases so does DBP 
or vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as age increases the 
FRS increases or vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as the SBP increases 
the FRS increases or vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as age increases so 
does BMI heart age or vice 
versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as SBP increases so 
does BMI or vice versa  
Represents a strong positive 
correlation indicating a 
significant positive linear 
relationship between the two 
variables; indicating that as 
LDL cholesterol increases so 
does TC or vice versa 
Represents a moderate 
negative correlation indicating 
a significant negative linear 
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DBP/HDL 
 
 
 
 
 
TG/DBP 
 
 
 
 
 
 
TG/TC 
 
 
 
 
 
TG/HDL 
 
 
 
 
 
 
FRS/DBP 
 
 
 
 
 
FRS/TC 
 
 
 
 
 
FRS/HDL 
 
 
 
 
 
BMI/SBP 
 
 
 
r (107) = -0.346, p < 0.000 
 
 
 
 
 
r (107) = 0.309, p < 0.001 
 
 
 
 
 
 
r (107) = 0.357, p < 0.000 
 
 
 
 
 
r (107) = -0.474, p <0.000 
 
 
 
 
 
 
r (107) = 0.486, p < 0.000 
 
 
 
 
 
r (107) = 0.473, p <0.000 
 
 
 
 
 
r (107) = -0.305, p <0.000 
 
 
 
 
 
r (107) = 0.340, p <0.000 
relationship between the two 
variables; as LDL increases 
HDL decreases or vice versa 
Represents a moderate 
negative correlation indicating 
a significant negative linear 
relationship between the two 
variables; as DBP increases, 
HDL decreases or vice versa   
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as TG’s increase, 
DBP also increases or vice 
versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as TG increases so 
does TC or vice versa 
Represents a moderate 
negative correlation indicating 
a significant negative linear 
relationship between the two 
variables; therefore as TG 
increases HDL decreases or 
vice versa  
Represents a moderate 
positive correlation indicating 
a significant linear relationship 
between the two variables; as 
FRS increases so does DBP or 
vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
correlation between the two 
variables; as FRS increases so 
does TC or vice versa 
Represents a moderate 
negative correlation indicating 
a significant negative linear 
relationship between the two 
variables; as FRS increases 
HDL decreases or vice versa  
Represents a moderate 
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BMI/DBP 
 
 
 
 
 
BMI/HDL 
 
 
 
 
 
DBP/FRS 
 
 
 
 
 
LDL/FRS 
 
 
 
 
 
TG/FRS 
 
 
 
 
 
Blood sugar/FRS 
 
 
 
 
 
 
BMI/TG 
 
 
 
 
 
 
 
 
 
 
r (107) = 0.334, p <0.000 
 
 
 
 
 
r (107) = -0.398, p <0.000 
 
 
 
 
 
r (107) = 0.486, p <0.000 
 
 
 
 
 
r (107) = 0.513, p <0.000 
 
 
 
 
 
r (107) = 0.377, p <0.000 
 
 
 
 
 
r (107) = 0.547, p <0.000 
 
 
 
 
 
 
r (107) = 0.321, p < 0.001 
 
 
 
 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as BMI increases 
SBP also increases or vice 
versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as BMI increases so 
does DBP or vice versa  
Represents a moderate 
negative correlation indicating 
a significant negative linear 
relationship between the two 
variables; as BMI increases, 
HDL decreases or vice versa  
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as DBP increases so 
does FRS or vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as LDL increases so 
does FRS or vice versa  
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as TG increases so 
does FRS or vice versa  
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as blood sugar 
increases so does the FRS or 
vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as BMI increases so 
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BMI/blood sugar 
 
 
 
 
 
BMI heart age/blood sugar 
 
 
 
 
 
 
BMI heart age/FRS  
 
 
 
 
 
 
BMI/BMI heart age 
 
 
 
 
 
 
 
r (107) = 0.379, p <0.000 
 
 
 
 
 
r (107) = 0.501, p <0.000 
 
 
 
 
 
 
r (107) = 0.895, p <0.000 
 
 
 
 
 
 
r (107) = 0.301, p <0.001 
does TG or vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as BMI increases so 
does blood sugar or vice versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as BMI heart age 
increases so does blood sugar 
or vice versa 
Represents a strong positive 
correlation indicating a 
significant positive linear 
relationship between the two 
variables; as BMI heart age 
increases so does FRS or vice 
versa 
Represents a moderate 
positive correlation indicating 
a significant positive linear 
relationship between the two 
variables; as BMI increases so 
does the BMI heart age    
 
 
Statistical analysis of the metrics acquired during the implementation of the EBP 
project have identified a cogent number of women who manifest modifiable risk factors 
and are therefore at increased risk for the development of CVD. The conundrum exists 
for practitioners regarding the interpretation of the data. The FRS has traditionally based 
CVD risk on the score percentage which, even with a multiple number of risk factors, still 
puts the percentage of having a CV event over the next ten years as being low, 
especially in younger women. The most current recommendation of identifying women 
as being at optimal risk, at risk, or at high risk may more accurately identify women who 
may benefit from lifestyle modification or early intervention. Identifying women as being 
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at risk or at high risk will hopefully cause practitioners to be more circumspect in 
screening and interpreting CVD risk in women.   
The descriptive data analysis and correlation data comparisons provide tangible 
conclusions that support the need for a clinical practice change. The PICOT question: In 
women ages 35-50 presenting for their annual gynecologic exam, who are asymptomatic 
for cardiovascular disease, how does implementation of the FRS model, compared to 
usual care (no screening), identify the level of CVD risk over a three month period of 
time? was saliently answered with the data analysis. The EBP project identified 91% of 
the study participants as having at least one modifiable risk factor for the development of 
CVD. The significance of each identified risk factor will be discussed in depth in chapter 
5. The standard of care in this clinical practice setting is opportunistic at best, meaning 
that a patient may be counseled on an elevated blood pressure, or history of smoking 
but all risk factors are not realized or inputted into a risk prediction model such as the 
FRS model. Dissemination of the EBP project findings to the administrative practice staff 
and medical providers will hopefully modulate a clinical practice change.  
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CHAPTER 5 
     DISCUSSION  
Despite progressive advances in our understanding of the determinants of 
atherosclerosis, cardiovascular disease (CVD) remains the leading cause of morbidity 
and mortality worldwide (Von-Khue, Martin, Blumenthal, & Blaha, 2012). The purpose of 
the evidence-based practice (EBP) project was to determine if applying the Framingham 
risk score (FRS) model to asymptomatic women would appropriately identify modifiable 
risk factors as well as their CVD risk percentage related to the probability of a CV event 
over the course of the next ten years. The clinical question to be answered was: In 
women ages 35-50 presenting for their annual gynecologic exam, who are asymptomatic 
for CVD, how does implementation of the FRS model compared to usual care (no 
screening) identify CVD risk over a three month period of time? The major goal of this 
primary prevention EBP project was to screen women without disease to identify and 
quantify their modifiable CVD risk factors. One of the cornerstones of health is to identify 
individuals who have an increased risk of developing an adverse outcome over a 
specific period of time so that they can be targeted for early preventive strategies 
(Ahmed, Debray, Moons & Riley, 2014).The EBP project implementation site was a large 
OB/GYN practice that while espousing to providing comprehensive women’s health care, 
was not implementing the recommended ACC/AHA preventive CV screening in their 
patient population. The outcomes of the EBP project demonstrate that application of the 
FRS model in asymptomatic women succinctly identifies modifiable risk factors and 
stratifies level of CVD risk into ideal CV risk, at risk, or at high risk for developing CVD. 
This chapter will articulate the EBP project findings from Chapter 4 and discuss the 
implications of the findings as they pertain to evidence-based APN clinical practice. 
Evaluation of the theoretical frameworks in relationship to this EBP project will be 
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conveyed as well as strengths and weaknesses of the EBP project, and implications for 
the future.  
Explanation of findings 
 Clinical trials have demonstrated that when CVD modifiable risk factors are 
treated and corrected, the chances of developing CVD are significantly reduced 
(D’Agostino, Pencina, Massaro, & Coady, 2013). The literature purports that CVD risk is 
multifactorial and synergistic over time for development of actualized disease. In order to 
potentially prevent CVD, risk factors in individuals without disease must be identified and 
quantified. Estimating risk plays an important role in understanding the underlying 
mechanisms involved in the etiology and progression of chronic disease and guides 
prevention and treatment (Kariuki, Stuart-Shor, & Hayman, 2013). As elucidated in the 
literature there are a myriad of risk prediction tools available to assess an asymptomatic 
woman’s risk of CVD. The ACC/AHA recommends a Framingham type global risk score 
that incorporates multiple traditional CV risk factors for all adult women without a history 
of CVD. The most current guidelines promulgated in the literature ascertain that for 
patients 20 to 79 years of age who are free from CVD, the first step is to assess for CVD 
risk factors (Goff, et al., 2013). CVD risk scores have the potential to educate and inform 
patients, motivate them to change their level of risk, and reinforce the importance of 
compliance with a plan of care.   
Of the 109 women who completed their laboratory testing and who’s data was 
evaluated using the FRS models, 91% (n=99) had at least one identified modifiable risk 
factor, 27% had two identified risk factors, 16% had three risk factors, 16% had four risk 
factors, 9% had five risk factors, 7% had six risk factors, 2% had seven risk factors and 
1% of the study participants had eight identified CVD risk factors. As a practicing 
clinician, each provider must critically evaluate the risk factors for their significance to the 
health of the patient. For example, having a single risk factor of elevated BMI may not 
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hold the same health consequence as an individual risk factor of a blood sugar of 300. 
Using one’s medical acumen and experience will guide the clinician in determining which 
patient needs immediate follow up and which ones can have their identified risk 
reviewed and discussed at the next appointment. It was determined from the critical 
valuation of the data that 50.5% (n=55) of the study cohort required timely follow up 
appointments for statistically significant identified risk factors. Clearly those individuals 
with significantly elevated blood sugar, blood pressure and cholesterol levels needed 
timely intervention with either lifestyle modification or lifestyle and medication modalities. 
The outcomes of the EBP project were correlative to those communicated in the 
CV literature using similar OB/GYN practice settings. The American College of 
Cardiology Foundation (ACCF) revealed results from a pilot study done in the OB/GYN 
setting which identified 69% of the study participants exhibiting significant CV risk (SCAI, 
2012). Another study that was implemented in ten different OB/GYN practice sites over a 
2 year period of time identified 87% of the study participants with significant CVD risk 
factors (Mehran & Yu, 2012). 
Correlational statistics using Pearson’s r exhibited twenty seven statistically 
significant relational correlations (p<0.001). The two variables being assessed occur 
naturally and are not manipulated or controlled by the project manager (Gravetter & 
Wallnau, 2008). These correlations were logically anticipated as they related to 
modifiable risk factors and how they interact to increase heart age, FRS percentages, 
and need for follow up. The results of the data analysis were statistically significant in 
both identification of risk factors and correlations between interval data variables. 
The single most identified CVD risk factor was BMI, with 76% (n=83) of the EBP 
project participants exhibiting a BMI ≥25 kg/m². These statistics from the EBP project are 
equivalent to those communicated in the literature. Statistics reported in both general 
scientific literature and CV literature confirm that two out of every three adults in the U.S. 
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are overweight or obese. There is a linear relationship between increasing BMI and all-
cause mortality, especially CVD related death (Von-Khue, Martin, Blumenthal, & Blaha, 
2012).  Each five unit increase in BMI was associated with a 29% increase in mortality in 
women (Dudina et al., 2011). This risk factor in isolation may not necessitate an 
immediate follow up appointment but it assuredly needs to be addressed at each 
subsequent patient appointment. BMI is a formidable risk factor that is also associated 
with an increased risk for the development of Type II diabetes, hypertension, and 
dyslipidemia, all of which are significant risk factors for CVD.  
To reiterate the findings reported in chapter four, the modifiable risk factors 
appraised included systolic blood pressure, diastolic blood pressure, total cholesterol, 
triglycerides, LDL cholesterol, HDL cholesterol, smoking, and BMI. Diastolic blood 
pressure was more significantly elevated than systolic blood pressure with 16% (n=17) 
of the study participants having elevated diastolic blood pressures and 6% (n=7) having 
elevated systolic blood pressures. All fractions of the lipid panel demonstrated significant 
abnormalities, with LDL cholesterol elevation being seen in the greatest number of study 
participants. As previously articulated LDL cholesterol has a deleterious effect on CVD 
health and is more discerning in the female population. 38% (n=41) of the participants 
had elevated total cholesterol, 20% (n=22) had elevated triglycerides, and 58% (n=63) 
had elevated LDL cholesterol. According to the study conducted by Ip (2009) greater 
than 50% of CV events are due to elevated cholesterol fractions. Elevated blood sugar 
of ≥100 was reported in 20% (n=22) of the project participants. Smokers constituted 
14.7% (n=16) of the EBP project participants. It was not ascertained the amount of 
cigarettes smoked or the duration of smoking history. Cigarette smoking is dose related 
and does significantly increase CVD risk in the female population.  
  The percentage of women who exhibited ideal CV health, as previously outlined 
by the AHA, was 9% (n=10) of the EBP project study participants. This is a higher 
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percentage than has been reported in the literature. A cohort study of 14515 adults 
revealed less than 1% of the participants possessed ideal CV health (Himmelbarb & 
Hayman, 2012). The remaining 91% of the EBP project participants were at risk for 
development of CVD. The most current recommendations outlined by the American 
Heart Association and the American College of Cardiology are to stratify women as 
being at ideal CV risk, at risk or at high risk versus reliance on the ten year risk 
percentage reported by the older FRS models. As has previously been discussed, 
women can exhibit a myriad of risk factors and still remain at a low risk percentage 
according to risk prediction models.  
Using the laboratory arm of the FRS prediction model, 42% (n=45) of the EBP 
project participants had a vascular heart age that was greater than their chronologic age 
and using the BMI arm of the FRS model 58% (n=63) of the project participants had a 
vascular heart age that was greater than their chronologic age. The rationale behind the 
two arms of the prediction model was the belief that many clinical practice settings were 
not implementing the laboratory screening but they could at least ascertain a level of risk 
from metrics obtained at the time of the patient visit. The vascular heart age is a 
persuasive metric to share with patients that seems to really make an impact on their 
understanding of how their heart is actually aging while not exhibiting overt symptoms of 
CVD.  
Descriptive demographics were completed on the n=109 who completed the 
laboratory testing as well as the n=39 who consented to participate but did not follow 
through with laboratory testing. The two groups were similar in all areas assessed 
including age, race, marital status, insurance status, smoking status, and family history 
of CVD. These similarities make the results generalizable to the target population.  
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Implications for clinical practice  
 CVD is well suited for application of primary prevention interventions due to it 
being common, occurring at a high incidence, that it can be modified by behavior, has a 
long latency period, and has a high economic and societal burden (Ashen, 2010). A 
practice grounded in evidence-based practice which integrates clinical expertise, patient 
history and values, and the best clinical evidence is an essential component of APN 
practice (Facchiano & Snyder, 2013). Implementation of EBP promotes high-value 
health care including enhancing quality and reliability, improving health outcomes, and 
reducing variations in care and cost (Melnyk, Gallagher-Ford, Long and Fineout-
Overholt, 2014). Utilization of EBP guidelines will ensure current knowledge is being 
used to guide cost-effective evidence based treatment options. The role of risk factors in 
the causal pathway to CVD provides a strong rationale for assessment and appropriate 
risk factor modification (Pearson, 2002).  
The most current clinical guidelines provide evidence for control of modifiable risk 
factors and use of primary prevention strategies in the clinical practice setting. Reducing 
the burden of CVD must be a shared responsibility among all health care providers. No 
longer can there be turf war or a non-committal ideology that it is not within the scope of 
practice to screen all women for heart disease risk. Screening must be initiated 
whenever and wherever the patient presents and the opportunity emerges. This clinical 
practice site purports to provide comprehensive care to women, in order to meet that 
tenet, it must assess and evaluate for the disease that is the leading cause of death in 
women. Clinical practice settings must also adhere to national guidelines that are 
authored by leading experts in the field of cardiology.  
Based on the achieved EBP project outcomes it is recommended to implement 
routine CV risk screening. The significant outcomes of this EBP project may result in like 
practices adopting CVD risk screening as part of their routine provision of women’s 
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health care. As previously elucidated, a cogent number of women consider their 
OB/GYN as their PCP, especially women of childbearing age. Unique to this OB/GYN 
practice is that a family nurse practitioner is a member of the medical provider team and 
possesses expertise in primary care and management of chronic medical conditions. It is 
a logical transition of care for patients with identified CVD risk to be referred to the FNP 
within the practice setting for treatment. 
Each patient encounter provides a fortuitous opportunity to educate women on 
the role of risk factors related to the development of CVD as well as broaden the patients 
understanding and knowledge of CV health. After initial assessment of risk, CVD risk 
must be reassessed throughout the lifespan. Applying principles of prevention with each 
patient encounter will improve health outcomes and reduce health care costs.  
Implications for the APN role 
 The principles of EBP are the cornerstone for APN’s to translate research 
findings into clinical practice and provide patients with the best available evidence to 
guide their healthcare decisions (Facchiano & Hoffman-Snyder, 2012). In a health care 
environment that has expectations of providing expedited care to a more complex 
patient population while remaining cognizant of cost containment, APN’s possess the 
competence, knowledge, and expertise to empower patients in understanding and 
incorporating EBP into their plan of care. As an APN, the ultimate goal of healthcare is to 
provide the best care possible to our patients, care that is grounded in research and is 
evidence-based. Implementation of EBP strategies may increase patient compliance in 
health promoting behaviors and decrease disease burden.  
Advance practice nurses play a pivotal role in the primary prevention of CVD in 
women. Exhibiting a leadership role in CV health, APN’s may need to challenge the 
status quo, lobby for health system reform, motivate and inspire other health 
professionals to engage in a shared vision for improving health and well-being in women 
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(Lanuza, Davidson, Dunbar, Hughes, & Geest, 2011). According to a study which 
surveyed women regarding CVD, only 21% of women reported that their health care 
provider had ever discussed their risk for CVD, reinforcing previous findings that health 
care providers underestimate CVD risk in women and underuse preventive therapies 
(Roberts & Davis, 2013).  
Office based CVD risk assessments are essential and cost effective in identifying 
modifiable risk factors and should be implemented as a routine part of the 
armamentarium of clinical practice. The aim of CVD risk assessment is to be more 
effective in identifying those at risk and to facilitate more efficient use of treatment and 
prevention resources (Owen & Reid, 2013). This EBP project reinforced evidence 
elucidated in the literature that CVD risk screening in women without disease is crucial in 
identifying CV risk. A substantially lower lifetime risk of developing CVD occurs among 
individuals with optimally controlled risk factors. It is noteworthy that individuals who 
reach middle age with optimal levels of all major risk factors have only a 6-8% remaining 
lifetime risk of developing CVD (Heidenreich et al., 2011). 
The APN must sharpen his/her CVD acumen, infuse evidence into the clinical 
practice setting, be able to effectively understand and communicate CVD risk, accurately 
administer and interpret risk prediction scores and its implications for the patient, and be 
actively involved with the patient in formulating a plan of care that incorporates evidence-
based risk prevention strategies. Once screening and risk has been ascertained, 
discussion of identified CVD risk factors is prima facie in reversing this devastating 
disease. Assisting the patient to understand their risk and facilitate a plan of care, the 
APN must utilize a number of educational tools and communication techniques. This is 
where the APN can effectively utilize the tenets of the health promotion model (HPM) to 
assist the patient in understanding their risk and identify methodologies to reserve that 
risk. In conjunction with their patients, APN’s can be instrumental in empowering their 
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patients to become proactive with health promotion and disease prevention, inclusive of 
CVD. APN’s as transformational leaders influence and engage individuals in a shared 
vision and provide innovative methods in which problems are viewed and solved 
(Lanuza et al., 2011).  
Clinical practice guidelines provide a foundational framework for the APN to 
screen their patients for CVD risk. The APN must familiarize herself with the guidelines 
and be fastidious in ongoing CVD risk assessment through the lifespan of their female 
patients. Using EBP constructs, APN’s can provide evidence and research regarding the 
symbiotic interaction of modifiable CVD risk factors and provide evidence based 
interventions to change CVD outcomes. According to Roberts and Davis (2013), 44-50% 
of the decrease in CVD mortality is related to risk factor reduction related to lifestyle and 
environmental changes such as blood pressure, blood sugar, cholesterol, BMI, and 
physical activity. APN’s can meld the triad of EBP tenets of evidence, such as clinical 
practice guidelines, clinical experience and knowledge, and patient preference to 
improve the CV health of women.  
Another germane tenet to APN practice is in fostering collegiality among their 
peers. The APN is continually being provided a fortuitous opportunity to share 
knowledge and expertise. APN’s must remain vigilant in remaining abreast of the most 
current evidence and research and must take advantage of every opportunity to be a 
conduit to share CV evidence at the professional, individual patient, and population level.  
Evaluation of applicability of the theoretical frameworks 
The EBP step wise approach assists the practicing APN in identification of a 
clinical question precipitating the APN to search for the most current relevant scholarly 
evidence as it relates to an identified clinical issue. Critical appraisal of the evidence for 
validity, reliability, and applicability to practice is essential for integration of the evidence 
into clinical practice (Melnyk, Gallagher-Ford, Long, Fineout-Overholt, 2014). If a 
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practice change is implemented based on the EBP process, it will be incumbent to 
disseminate the evidence and foster an environment that is conducive for change. In 
order for the EBP project to become a permanent paradigm shift in clinical practice there 
must be continuous monitoring and ongoing evaluation of the EBP change.  
The five phases of the Stetler model for EBP were used as the underpinning to 
facilitate progression of the EBP project. The model outlines a number of critical thinking 
and decision making steps to assist the DNP student in effectively implementing an EBP 
project. Stetler’s model de-emphasizes practice based on tradition and instead stresses 
use of research findings as well as other sources of credible information (Stetler, 2001). 
This foundational framework was inclusive of: a) preparation; b) validation;                     
c) comparative evaluation and decision making; d) translation and application; and            
e) evaluation (Ciliska et al., 2011). This framework was an appropriate fit and was used 
successfully to promote, design, implement, and evaluate the EBP project.  
In the preparatory phase of the model, the clinical question is identified and 
formulated for its potential influence in clinical practice. Affirmation of the clinical 
question as a clinical priority was ascertained. Women’s cardiovascular health has been 
touted as a health priority in this practice setting for many years but implementation of 
risk prediction screening had never come to fruition. It was imperative during this phase 
of the process to examine both external and internal factors that may exert influence in 
the EBP project. A critical and exhaustive search of the evidence reinforced the 
necessity for screening asymptomatic women for CVD risk. The relevant literature 
provided credence to the significance of the EBP project and mitigated the development 
of expected outcomes and goals. The PICOT question was formulated and defined.  
Phase two of the Stetler model assisted the EBP project manager in critical 
appraisal and grading of the evidence that was garnered during the first phase. The 
appraised literature revealed an appropriate number of high level evidence studies. 
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Several appraisal tools were utilized in the evaluation of the evidence including the 
AGREE II, CASP, and Melnyk & Fineout-Overholt’s (2011) rapid appraisal checklist. 
Assimilation of the evidence resulted in 20 articles that were included in the evidence 
table. The evidence was inclusive of 14 Level I evidence studies, four Level IV evidence 
studies, and two Level VI evidence studies. 
Phase three of the EBP model had the project manager analyzing and coalescing 
the evidence for the best clinical practice fit. Involvement of the management staff, CEO, 
and marketing director as influential stakeholders were included in the dissemination of 
evidence supporting the need for and expected outcomes of the EBP project. A decision 
regarding the risk prediction tool, format for implementation, as well as expected 
outcomes were based on the appraisal of the evidence.  
In phase four of the model, implementation; the project manager designed the 12 
week primary prevention intervention based on the significance of the clinical issue and 
the identified need for a clinical practice change. IRB approval was obtained from 
Valparaiso University and the process for the EBP project implementation was 
presented to and approved by the CEO and management team of the clinical practice 
site. Education was completed with the medical office staff, the nursing staff, and the 
administrative staff at the implementation site. Education was rendered via power point 
presentations, scripted modules, role playing, and question and answer time.  
The fifth and final phase of the Stetler model was to amalgamate the statistical 
data and promulgate the findings. Change strategies were evaluated and implemented 
in preparation for a clinical practice change. Critical evaluation of the entire EBP process 
was completed by the EBP project manager including strengths and weaknesses of the 
project, use of the theoretical frameworks, and implications for clinical practice. These 
tenets will be expounded upon in the following sections.  
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According to the 2012 AHA National Survey by Mosca and colleagues, women 
engaged in preventive behaviors to improve their health and feel better, not to live longer 
(Roberts & Davis, 2013). Thirty five percent of the women surveyed by Mosca and 
colleagues reported that they had no barriers to engaging in preventive behaviors and 
felt they lived a heart healthy lifestyle. In the remaining sixty five percent, lack of time, 
family obligations, lack of financial resources, and lack of confidence in their ability to 
achieve behavior change were cited as barriers to a heart healthy lifestyle (Roberts & 
Davis, 2013). Once risk is estimated, understanding and communicating risk is 
acknowledged as being a daunting task. Practitioners must be cognizant of a myriad of 
interpretations as to what constitutes health and health promoting behaviors and what 
influences affect each individual patient. Practitioners must be mindful that self-esteem, 
societal support, social status, family values and views, as well as one’s own personal 
control over their health all interact in health promotion. Acknowledgement by women 
that CVD is the leading cause of death in their gender will support the impetus for 
primary prevention and identification of modifiable risk factors and ultimately empower 
women to become proactive in their health. The APN ideally wants to instill CVD 
prevention strategies in patients with the ultimate intent of preventing negative health 
outcomes.  
Pender’s health promotion model (HPM) served as an excellent foundational 
nursing model for this EBP project cohort to actively participate in health promoting 
behaviors. The components of the model lead to a logical progression of the concepts 
needed to improve health and health behaviors and support the belief that health 
behaviors must be in control of the patient and have meaning to the patient in order to 
be effective (Bennett, Perry & Lawrence, 2009). The HPM can be used to increase 
perception of CVD risk and facilitate conversation regarding health beliefs and 
behaviors. Implementing the HPM can serve as a conduit to change health from a 
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paradigm of disease management to one of health promotion and disease prevention. 
APN’s must be creative and innovative in developing strategies that will break down 
identified barriers and allow patients to participate and be proactive in a heart healthy 
lifestyle. The HPM adequately pulls together the factors that can motivate and engage 
the patient in establishing and monitoring goals and increase adherence to positive 
health behaviors.  
Strengths of the EBP project 
 The fundamental tenet to successful implementation of EBP resides in an 
organizational culture that finds value in EBP and is supportive of EBP implementation. 
The main strength of this EBP project was a practice environment that supported the 
EBP project and a supportive provider and administrative staff who collaborated with the 
EBP project manager in navigating the project implementation. The DNP project 
manager provided credibility for the EBP through extensive research and critical 
appraisal of the CVD literature. The project manager articulated the significance and 
background of the project, the scientific evidence to support the EBP, the tool to be 
implemented, and the expected outcomes of the EBP project to the key stakeholders. 
The relevance of the health issue as a health priority, the amount of evidence supporting 
the health priority, and the ease with which the EBP project can be replicated enhanced 
the strength of the project. Critically evaluating the EBP throughout the implementation 
phase supported the implications that the EBP project had to practice issues, research, 
theory, and education. The EBP project goals and objectives were in alignment with the 
vision and mission of the clinical practice setting. The foundational basis of the EBP 
project using the Stetler model and the HBM provided a sound theoretical framework 
from which to develop, implement, and evaluate the EBP project.  
 Ease of implementation of the EBP project into the clinical practice site was an 
identified strength. There was minimal interruption of normal work flow by the clinical or 
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provider staff. The clinical staff felt well educated on the implementation process and 
was enthusiastic and comfortable in identifying potential study participants, educating 
them, and obtaining informed consent. There were no overtime hours needed for 
implementation of the EBP project and the associated costs were miniscule, mainly 
consisting of nominal office supplies.  
The literature is saturated with studies validating the reliability and usefulness of 
the FRS model as a gold standard CVD risk prediction tool. The tool was easily 
implemented into the clinical practice site and inputting of metrics into the web-based 
program provided a quick analysis of the variables and rapid reporting of the findings. 
The ability of being able to scan the reports into the patients EMR provided accessibility 
for all providers to view the FRS results at any point along the continuum of care. As part 
of this EBP project, the project participants were sent thank you letters, applauding them 
for being proactive in their heart health, and were provided with copies of their FRS 
results along with an explanation of the findings. Providing the patient with a tangible 
visual result reinforced the findings and provided a mechanism for the patient to evaluate 
their results without the time constraints of an office appointment. Another identified 
strength of the FRS tool is its reporting and explanation of heart age which provided in 
layman terms how the individuals’ heart was aging. Vascular heart age is intuitively an 
easily understood way of illustrating the likely reduction in life expectancy if risk factors 
are not reduced.  
Utilizing the EMR to calculate risk automatically will become the mainstream of 
current and future risk algorithms (Goff et al., 2013). Using the EMR as a method for all 
members of the health care team to review the results of the risk screening and to alert 
the practitioner of when screening needs to be redone will aide in the ongoing diligence 
of continued implementation of this EBP practice change and well as pervasive 
awareness to CV health.  
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Limitations of the EBP project 
 Implementation in only one of five clinical practice settings was a limitation that 
was identified with the EBP project. Since this OB/GYN practice has several locations 
around the geographical area, the demographics will vary to a certain extent. For 
example, the demographic of the EBP project implementation site consisted of  
approximately 65% commercially insured patients, 25% Medicaid, 6% Medicare and 4% 
uninsured while our inner city clinical practice site is composed of approximately 60% 
Medicaid patients, 20% commercially insured, 5% Medicare, and 15% uninsured. Once 
the EBP project becomes a permanent clinical practice change, women at all clinical 
sites will be offered and screened for CVD risk.  
The EBP project sample was a convenience sample of women and therefore may 
exhibit participation bias. Many studies have demonstrated that those who volunteer for 
screening may be healthier than the general population (Gordis, 2009). Another potential 
bias may be identification of those in the pre-clinical phase versus those close to 
exhibiting overt disease. Because CVD has a long prodromal phase, younger patients 
may be healthier than those who are older and possibly closer to exhibiting overt 
disease therefore exhibiting various degrees of risk. The longer the preclinical phase, the 
more likely the screening program is to detect the case while it is still preclinical (Gordis, 
2009). Attrition is a concern while implementing any type of research or EBP. Originally 
148 women signed the consent form to participate in the EBP but 109 actually 
completed the laboratory portion of the project for a participation rate of 73.6%. 
Demographics were compared between the two groups and demonstrated that they 
were comparable in all areas of demographics.  
There are limitations to any of the risk prediction models, namely that they are 
most effective within the population from which they were derived and the 
outcomes/end- points that they attempt to address. The literature identifies over one 
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hundred CVD risk prediction models. No one model assesses all of the variables that 
have been associated with CVD risk. The question can be posed if a different tool would 
yield a different result within the same sample population. However, as has been 
previously articulated, the risk prediction tool must effectively assess multivariate CVD 
risk but be cost-effective and be easily implemented in the clinical practice setting. 
Regardless of the tool, the general principal remains the same, namely to accurately 
predict the risk of future occurrence of an outcome in an individual utilizing the values of 
multiple characteristics (Ahmed, Debray, Moons, & Riley, 2014). One of the major 
limitations of the FRS model articulated in the literature is its potential for under-
estimating risk, especially in younger populations. However the FRS remains a gold 
standard tool for use in the clinical setting to identify and stratify CVD risk. 
Implementation of the Framingham risk predictive tool identifies CVD risk and allows the 
practicing clinician to implement further EBP prevention guidelines or refer the patient to 
another clinician for further assessment and/or treatment.  
Another limitation of risk prediction models is that many of them are neither gender 
nor ethnically specific and therefore may not be representative of the general population. 
This is especially poignant in minority populations who historically have a 
disproportionate risk for CVD. Fortunately the FRS model does predict gender specific 
levels of risk but is not ethnicity specific scores. CVD risk and health outcomes are 
influenced by environmental, social, economic, and biologic factors (Lanuza et al., 2011) 
which are not reflected in our current risk predictive tools.   
Another limitation to the risk prediction models is in their definition of risk level. It is 
discerning the magnitude of risk factors exhibited by women, especially those under the 
age of 50, who still do not reach a high percentage of CVD risk as defined by some risk 
prediction models. It is certainly more prudent to follow the tenets as outlined by the 
ACC/AHA, which is to define women as being at ideal risk, at risk, or at high risk for 
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development of CVD. The various delineations of risk levels can be confounding for the 
practicing clinician and is often a cited reason for not implementing risk screening in the 
clinical setting. A standardization of values and tools would allow for greater ease of 
implementation.  
Barriers to implementation of EBP in the clinical setting are many and may include 
time constraints, organizational culture and philosophy, inadequate EBP knowledge, lack 
of access to databases for evidence searching, leader resistance, work load, and limited 
access to resources that facilitate EBP (Melnyk, Gallagher-Ford, Long, & Fineout-
Overholt, 2014). Other barriers may include lack of reimbursement for preventive care, 
lack of incentives to practice primary prevention, lack of understanding and skill at 
implementing the various risk prediction models, and lack of understanding in 
interpreting and communicating the findings. Barriers to implementation may also come 
from the patients themselves who may be reticent to screening or implementing lifestyle 
changes. Change strategies must be implemented within the clinical setting to eradicate 
barriers to EBP.  
Implications for the future 
Practice. Strategies for implementation and sustainability of EBP need to be 
multi-faceted to include education and knowledge enhancement, cultivation of an 
organizational culture of EBP, development of EBP leaders and mentors, resource 
availability, expectation of initiating an EBP environment, and recognition for 
engagement in EBP (Melnyk, Gallagher-Ford, Long, & Fineout-Overholt, 2014). The 
intended effect of EBP is to standardize healthcare practices to science and best 
evidence and to reduce illogical variation in care, which is known to produce 
unpredictable health outcomes (Quigley, Huston, & Covell, 2013). Aligning with the 
recommendations from the Institute of Medicine and providing quality of care, EBP 
unifies research evidence with clinical expertise and encourages individualization of care 
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through inclusion of patient preferences (Quigley, Huston, & Covell, 2013). Combining 
national guideline recommendations or pathways backed by current research, APN’s will 
consistently be providing comprehensive evidence-based care to their patients.  
Since the first screening guidelines for screening women for CVD risk were 
published in 1999, there continues to be a pervasive disconnect between nationally 
recommended CVD risk screening and implementation of guidelines in clinical practice. 
According to Perk (2012), 62% of physicians used subjective assessments to gauge CV 
risk rather than employ a risk calculator. Approximately 60% of PCP’s and OB/GYN’s 
state that they were aware of the ACC/AHA evidence-based CVD screening guidelines 
yet only 39% of PCP’s and 21% of OB/GYN’s reported incorporating the guidelines into 
clinical practice (Wells & Kalman, 2011). This is reflected within the EBP project 
implementation site, no consistent CVD risk screening was being done. Debate 
continues as to who is responsibility to initiate screening, is the responsibility of only the 
PCP or should anyone who interacts with the patient take the initiative to institute CVD 
risk screening? Death rates for women 35 to 54 years of age are trending upward, 
compared with the previous four decades (Carey & Gray, 2012). Unless the 
determinants of CVD risk are identified and reversed, CVD rates in women will continue 
to trend upward. Unfortunately, OB/GYN practitioners were reported to substantially 
have less awareness of national CVD screening guidelines than other medical 
practitioners (Carey & Gray, 2012). The commonly held belief that OB/GYN practices 
focus only on reproductive and breast health must be reversed and this clinical specialty 
must place emphasis on comprehensive women’s health care including screening for 
CVD risk.  
The outcomes of the EBP project demonstrated its effectiveness in identifying 
CVD risk in asymptomatic women. Implementing CVD risk assessment screening in this 
clinical practice setting requires an educational protocol and a referral process for 
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patients with identified high levels of risk. The clinical practice site used for 
implementation of this EBP project is in the process of looking to partner with an internal 
medicine or cardiology practice in an effort to provide a seamless system for the patient 
and improve transitions in care. Utilizing the EMR provides a straight forward method to 
view CVD risk screening results, track risk screening dates, and to alert the practitioner 
as to when CVD risk screening needs to be redone.  
Theory. The theoretical frameworks that served as a guide for this EBP were 
applicable and effective throughout the EBP process. An interesting article published in 
the NEJM (2014) found that women often viewed their risk or development of CVD as 
the consequence of having done something bad; that it was essentially their fault 
whereas cancer was something bad that happened to them but not caused by them. 
Future theory development or application of current theory should focus on this 
perception of risk and work to expand knowledge regarding CVD and its associated risk 
factors.   
 As the first estimation of risk for CVD, calculating the FRS is clinically helpful in 
identification of individuals at high or low risk, however those at intermediate risk may 
need further risk stratification with additional testing. If risk is identified, additional testing 
could be performed such as lipoprotein subfractions, CRP-hs, or imaging modalities. 
There are a myriad of theoretical models that can be applied by the APN in 
clinical practice. Nursing theories must be continually applied to future research 
endeavors to assess their validity and applicability to practice issues. Use of the HPM is 
applicable to this EBP project and population because once risk is identified, it is 
imperative to find the impetus for the patient to make changes in their health behavior to 
reverse the identified risk.    
Research. For risk prediction models to become common place in clinical 
practice, research needs to show that they consistently have a positive impact on health 
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outcomes (Ahmed, Debray, Moons, & Riley, 2014). Additional research needs to be 
rendered to determine the role and inter- relatedness of all associated CVD risk factors. 
Research needs to demonstrate that identified level of risk is indeed associated with 
development of disease and if the level of risk is decreased, that there a commensurate 
decrease in disease development. Additional research needs to be executed regarding 
significance of identified risk factors as they relate to a younger population. This EBP 
project assessed women 35-50 for early identification of CV risk; however the literature 
is unmistakable regarding increased rates of obesity and type II diabetes manifesting in 
younger individuals, even children. This discerning data trend will cause an increase in 
CVD among younger individuals and research must focus on assessment and 
interventions for this younger age group.   
Although there are over one hundred CVD risk prediction models reported in the 
literature, there is currently not one tool that evaluates all identified CVD risk factors as 
they relate to women. As articulated in chapter two, evidence is informed in the literature 
on risk factors such as family history, LDL cholesterol, diet, and physical activity which 
are not reflected in the FRS model, yet are consequential in the development of CVD. 
Future research endeavors must focus on the role of all identified CVD risk factors and 
focus on identification of which variables are the most important for risk prediction.  
Although the FRS model is gender specific, is validated and reliable in the U.S. 
population, and is a recommendation in clinical practice guidelines, is does not 
encompass all risk factors that play a pivotal role in the development of CVD in women 
nor is it ethnically diverse. Research is ongoing with new risk prediction models that will 
add additional variables as well as genetic markers which may enhance the 
determination of risk prediction outcomes. Addressing risk factors suspected as being 
more significant in the female gender may also be ponderous for future research 
endeavors. For example, CPR-hs may add prognostic information for a woman’s 
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development of CVD. Sharma and Gulati (2013) report on a study where women with 
elevated CRP-hs had almost twice the risk of future CV events than those with normal 
CRP-hs. Women with history of pre-eclampsia have double the risk of subsequent 
ischemic heart disease, stroke, and venous thrombotic events (Sharma & Gulati, 2013) 
making this a crucial component of comprehensive patient history taking and an area for 
continued research.  
Additionally, research must continue on the cost effectiveness of early screening 
and intervention. Targeted research must include assessment across ethnic and 
culturally diverse groups. It is elucidated in the literature that African American women 
and Hispanic women have a disproportionately higher rate of CVD than Caucasian 
women, with Hispanic women exhibiting overt CVD ten years earlier than Caucasian 
women (Ahmed, Debray, Moons, & Riley, 2014). Healthcare that is designed to prevent 
illness and minimize progression of disease is imperative to improve quality of life and 
decrease healthcare costs.  
Education. The prevalence of CVD will increase by approximately 10% in the 
next 20 years under status quo CVD prevention while treatment trends and direct costs 
related to CVD will increase three fold (Himmelfarb & Hayman, 2012). Cardiovascular 
disease education must be approached from a myriad of perspectives. Continuing to 
update the medical providers and office staff on the most current CV literature and 
research will keep them apprised of the most up to date information regarding CV health 
and trending. Remaining active in professional organizations and sharing expertise and 
knowledge with colleagues is imperative to increase awareness of CVD. CV education 
must also be approached from both an individual and population or community level. 
Each patient encounter provides an opportunity to assess lifestyle behaviors and allows 
meaningful interaction on the consequences of poor lifestyle choices. Primary prevention 
education must be succinct and continuous to educate the individual and effect change 
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in behavior. Being actively involved in population awareness endeavors will expand the 
knowledge of CVD within the community. Being active politically with professional 
organizations and in policy reform will expand awareness of primary prevention 
strategies. Prevention initiatives at the population level such as lifestyle education, stress 
reduction, physical activity education, school lunch program changes, senior education, 
and smoking cessation will aid in the reversal of CVD. Participating in community health 
fairs and community educational forums and health talks allows the practitioner to share 
their cardiovascular knowledge and expertise.  
The results of this DNP EBP project identified a significant number of women 
with undiagnosed CVD risk factors. Having a penchant for prevention, had this project 
not been implemented, these women would not have been identified as being at risk for 
the development of CVD. Only through early identification of risk can the trajectory of 
CVD be reversed. The correlational relationships were expected, if there was a 
significantly elevated blood sugar, blood pressure, or lipid panel, there was a 
commensurate increase in risk percentage and vascular heart age. The vascular heart 
age was the strongest motivating factor for women to verbalize a desire to make lifestyle 
changes. Risk percentages had little effect on the patient understanding of their risk, but 
a visual depiction of how their heart was aging was eye opening for many of the patients. 
Even the other medical practitioners in the practice found the vascular heart age an 
interesting tenet and something the patient could understand and relate to. My fellow 
colleagues have found the results of the EBP project extremely informative and concur 
that this practice setting is an ideal clinical site for early screening and identification of 
CVD risk factors and has the potential to appropriately prognosticate and to increase 
awareness, education and prevention related to CV health. Implementation of CVD risk 
screening in this OB/GYN setting sets us apart from the practice of other OB/GYN 
settings and strengthens our commitment to our mission and vision statements. The 
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results of the EBP project provide compelling evidence for making CVD risk screening a 
permanent practice change.  
Conclusion 
For a woman to reduce her CV risk, she first has to believe it exists (Rosenbaum, 
2014). It is well recognized in the cardiovascular literature that a need exists for a risk 
assessment approach that can easily be utilized by medical providers in the clinical 
practice setting. Cardiovascular disease has a long latency period therefore the greatest 
benefit would be achieved by effective early primary prevention. The deleterious impact 
of CVD in women is largely related to modifiable CVD risk factors. Risk factor 
modification is tightly linked to knowledge of heart disease and use of preventive actions 
by women who are at risk (Roberts & Davis, 2013). 
Despite progressive advances in our understanding of the determinants of CVD, 
it remains the leading cause of morbidity and mortality worldwide (Van-Khue, Martin, 
Blumenthal, & Blaha, 2012). By 2030, it is predicted that more than 40% of Americans 
will have some form of heart disease with associated economic costs increasing from 
$273 billion in 2008 to $818 billion in 2030 (Facchiano & Hoffman-Snyder, 2012). As has 
been repeatedly elucidated throughout this paper, the literature is salient in identifying 
80-90% of CVD risk as being preventable. The statistical findings from this EBP project 
support the findings reported in the literature, 91% of the study participants exhibited at 
least one CVD risk factor with 50.5% exhibiting three or more risk factors necessitating a 
timely follow up appointment. The most poignant outcome of the EBP project is the 
salient number of women who were previously undiagnosed with CVD risk but now have 
had their CV risk identified.  
The reality exists that CVD is expected to escalate because of the aging 
population, obesity, metabolic syndrome, and diabetes which are all health issues that 
affect women disproportionately (Carey & Gray, 2012). Many U.S. women consider their 
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gynecologist as their PCP and as such, practitioners in this clinical setting must strive to 
provide screening to their patient population.  
Implementing the methodology of the EBP process, this EBP project succinctly 
identified a clinical issue, critically appraised the literature, identified best practice 
recommendation and in a logical methodological approach applied the steps of the EBP 
to the clinical question. The resultant analysis of the data provided tacit evidence that 
supported the significance of the identified clinical question and provided outcomes that 
support the need for CVD risk screening to become a permanent clinical practice 
change.  
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Appendix A: Data Collection Form 
 
Screening Cardiovascular Risk 
 
 
Name______________________________________ 
 
Age________________________________________ 
 
Race_______________________________________ 
 
Family history of heart disease in first degree relative before the age of 55    Yes or No 
 
Smoker  Yes or No 
 
Blood pressure_______________________________ 
 
BMI________________________________________ 
 
Blood glucose________________________________ 
 
Total cholesterol______________________________ 
 
LDL_________________________________________ 
 
Triglycerides_________________________________ 
 
HDL________________________________________ 
 
FRS level of risk_______________________________ 
 
Heart age____________________________________ 
 
Follow up appointment  Yes or No 
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Appendix B: Consent form 
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Appendix C: Thank you letter for normal results 
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Appendix D: Thank you letter for abnormal results requiring follow up appointment 
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Appendix E: Thank you letter, abnormal BMI 
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Appendix F: Framingham risk score results based on laboratory testing 
From The Framingham Heart Study   Enter Values Here   
General CVD Risk Prediction    
 
 
  
      
Risk Factor Units 
 (Type Over Placeholder 
Values in Each Cell) Notes 
Sex male (m) or female (f) f   
Age years 38   
Systolic Blood Pressure mmHg 148.0   
Treatment for Hypertension yes (y) or no (n) n   
Smoking yes (y) or no (n) y   
Diabetes yes (y) or no (n) n   
HDL mg/dL 36   
Total Cholesterol mg/dL 212   
  
  
  
Your 10-Year Risk  
(The risk score shown is derived on the basis of an equation.  Other 
print products, use a point-based system to calculate a risk score that 
approximates the equation-based one.)   
8.4% 
  
 
Your Heart/Vascular Age  
 
68 
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Appendix G: Framingham risk score results based on BMI  
From The Framingham Heart Study   Enter Values Here   
General CVD Risk Prediction    
 
 
  
      
Risk Factor Units 
 (Type Over Placeholder 
Values in Each Cell) Notes 
Sex 
male (m) or female 
(f) f   
Age years 38   
Systolic Blood Pressure mmHg 148.0   
Treatment for Hypertension yes (y) or no (n) n   
Smoking yes (y) or no (n) y   
Diabetes yes (y) or no (n) n   
Body Mass Index kg/m² 38.86   
  
  
  
  
  
  
Your 10-Year Risk  
(The risk score shown is derived on the basis of an equation.  Other print 
products, use a point-based system to calculate a risk score that 
approximates the equation-based one.)   
7.8% 
  
 
Your Heart/Vascular Age  
 
63 
  
 
 
   
    
    
    
    
    
    
    
    
    
     
